Allergan Confidential Protocol 192024 -093Amendment 7
2 GDD -TA-T-004 v2015.10The foll owing information can be found on FDA  Form 1572 and/or study  contacts page :  
Name [CONTACT_3669] [CONTACT_287440] y per
sonnel and Em ergency  Telephone 
Numbers ; name, address, and statement of qualifications of each investigator; name [CONTACT_358232]; name [CONTACT_287472]; name [CONTACT_358233]; US 21 CFR 312.23 
section 6(iii)b.
Allergan Confidential Protocol 192024 -093Amendment 7
3 GDD -TA-T-004 v2015.10INVESTIGA TOR SIGNA TURE P AGE
INVESTIGATOR:
I agree to:
Impl ement and conduct this study  diligentl y and in strict compliance with the protocol, 
good clinical practices and all applicable laws and reg ulations.
Maintain all information supplied by  [CONTACT_249595], when this information 
is submitted to an I nstitution al Review Board (IRB), Independent Ethics Committee 
(IEC) or another group, it will be submitted with a designation t hat the mate rial is 
confidential.
Ensure that all persons assisting with the trial are adequatel y informed about the protocol, 
theinvestig ational product(s), and their trial- related duties and functions.
I have read this protocol in its entirety  and I agr ee to all as
pects .  
Investigator Printed Name [CONTACT_358234] [ADDRESS_446732] (LUMIGAN®)
................................................................................... [ADDRESS_446733] SR ................................ ........................ 29
1.3 Study Rationale ...................................................................................................... 30
2.Study Objectives and Clinical Hypotheses ...................................................................... 31
2.1 Study Objectives .................................................................................................... 31
2.2 Clinical Hy potheses ............................................................................................... 31
3.Study Design .................................................................................................................... 32
4.Study Population and Entry Criteria ................................................................................ 33
4.1 Number of Patients ................................................................................................. 33
4.2 Study Population 
Characteristics ........................................................................... 33
4.2.1 Patients with Sickle 
Cell Trait/Disease or Other Hemoglobinopathies ..... 33
4.3 Inclusion Criteria.................................................................................................... 33
4.4 Exclusion Criteria ................................................................................................... 35
4.5
Permissible and Prohibited Medications/T reatments ................................ ............. 38
4.5.1 Permissible Medications/T reatments ................................ ......................... 38
4.5.2 Prohibited Medications/T reatments ........................................................... 40
4.5.3 Definition of Females of (Non -)Child bearing Potential and/or Acceptable 
Contraceptive Methods .............................................................................. 42
5.Study T reatments ................................ ................................ ................................ ............. 43
5.1 Study T reatments and Formulations ................................ ................................ ....... 43
5.2 Control Treatment .................................................................................................. 43
5.3 Methods for Masking ............................................................................................. 43
5.4 Treatment Allocation Ratio and Stratification ........................................................ 44
5.5 Method for Assignment to Treatment Groups/Randomization .............................. 44
5.6 Treatment Regimen ................................................................................................ 44
Allergan Confidential Protocol 192024 -093Amendment 7
5 GDD -TA-T-004 v2015.105.7 Storage of Stud y Medications ................................................................................ 45
5.8 Preparation of Stud y Medications/T reatments ................................ ....................... [ADDRESS_446734] SR Administration ................................................................. 46
5.9.2 SLT Administration .................................................................................... 49
6.
Response Measures and Summary  of Data Collection Methods ................................ ..... 50
6.1 Efficacy  Measures .................................................................................................. 50
6.1.1 Primary  Efficacy  Measure ................................ ................................ .......... 50
6.2 Safety  Measures ..................................................................................................... 51
6.3 Other Measures ...................................................................................................... 54
6.3.1 Medical History , Phy sical Examination, and Vital Signs ........................... 54
6.3.2 Pregnancy  Testing ...................................................................................... 55
6.3.3 Laboratory  Procedures ............................................................................... 55
6.4 Other Study Supplies .............................................................................................. 56
6.5 Summary  of Methods of Data Collection ................................ .............................. 57
7.Statistical Procedures ....................................................................................................... 57
7.1 Analy sis Populations .............................................................................................. 58
7.2 Collection and Derivation of Primary  and Secondary  Efficacy  Assessments ........ 58
7.2.1 Primary  Efficacy  Variable .......................................................................... 59
7.2.2 Secondary  Efficacy  Variables ..................................................................... 59
7.2.3 Other Efficacy V ariables ............................................................................ 59
7.3 Hypothesis and Methods of Anal ysis..................................................................... 59
7.3.1 Primary  Efficacy  Analyses......................................................................... 60
7.3.2 Secondary  Efficacy  Analyses..................................................................... 61
7.3.3 Other Efficacy Analyses............................................................................. 62
7.3.4 Safety  Analyses .......................................................................................... 62
7.4 Subgroup Anal yses................................ ................................ ................................ . 63
7.5 Sample Size Calculation ................................ ................................ ........................ 63
7.6 Inter im Anal yses..................................................................................................... 63
8.Study Visit Schedule and Procedures ................................ ................................ .............. 63
8.1 Patient Entry  Procedures ........................................................................................ 65
8.1.1 Overview of Entry  Procedures ................................ ................................ ... 65
8.1.2 Informed Consent and Patient Privacy ................................ ....................... 65
8.2 Washout I ntervals ................................ ................................ ................................ ... 65
Allergan Confidential Protocol 192024 -093Amendment 7
6 GDD -TA-T-004 v2015.108.3 Procedures for Final Study Entry ................................ ................................ ........... 66
8.4 Visits and Associated Procedures ........................................................................... 67
8.4.1 Screening V isit........................................................................................... 67
8.4.2 Baseline V isit............................................................................................. 69
8.4.3 Treatment Period ........................................................................................ 70
8.5 End of Study ........................................................................................................... 78
8.6 Instructions for the Patients .................................................................................... 78
8.7 Unscheduled V isits................................ ................................ ................................ . 79
8.8 Compliance with Protocol...................................................................................... 79
8.9 Early Discontinuation (Early Exit) of Patients ................................ ....................... 79
8.10 Withdrawal Criter ia................................ ................................ ................................ 80
8.11 Study T ermination .................................................................................................. 80
9.Adverse Events ................................................................................................................ 80
9.1
Definitions.............................................................................................................. 81
9.1.1 Adverse Event ............................................................................................ 81
9.1.2 Serious Adverse Event ............................................................................... 81
9.1.3 Severity ...................................................................................................... 82
9.1.4 Relationship to Study  Drug, Device, or Procedure .................................... 82
9.2 Procedures for Reporting Adverse Events ............................................................. 83
9.3
Procedures for Reporting a Serious Adverse Event ............................................... 83
9.4 Procedures for Unmasking of Stud y Treatment ..................................................... 84
10.Administrative I tems ................................ ................................ ................................ ....... 84
10.1 Protection of Human Patient s................................................................................. 84
10.1.1 Compliance W ith Informed Consent Regulations ( US 21 CFR Part 50) and 
Relevant Country  Regulations ................................................................... 84
10.1.2 Compliance W ith IRB or I EC Regulations ................................................ 85
10.1.3 Compliance W ith Good Clinical Practice .................................................. 85
10.1.4 Quali ty Assurance ...................................................................................... 85
10.1.5 Compliance W ith Electronic Records; Electronic Signatures Regulations 
(US 21 CFR Part 1 1) .................................................................................. 85
10.2 Changes to the Protocol ......................................................................................... 85
10.3 Patient Confidentiality ................................ ................................ ........................... 86
10.3.1 Patient Privacy ........................................................................................... 86
10.4 Documentation ....................................................................................................... 86
10.4.1 Source Documents ..................................................................................... 86
Allergan Confidential Protocol 192024 -093Amendment 7
8 GDD -TA-T-004 v2015.10Table 6 Schedule of V isits and Proc edures:  Month 13 through Month 24/Exit ......... 23
Table7 Minimum Washout Period by  [CONTACT_358180] ........................ 66
Table 8 Administration C ycle 3 Schedule of V isits and Procedures (only  for patients 
who reached W eek 32 prior to implementation of Amendment 3) ............... 157
Allergan Confidential Protocol 192024 -093Amendment 7
9 GDD -TA-T-004 v2015.10Protocol Summary
Study Compound :  
Bimatoprost sustaine d release (S R) implants containing preservati ve-free bimatoprost 
(AGN -192024)
Phase :  3
Study Objective:  To evaluate the intraoc ular pressur e (IOP) -lowering effect and safety of Bimatoprost SR 
compared with selective laser trabeculoplasty (SLT) i n patient s with open -angle glaucoma (OAG) or ocular 
hypertension (OHT) who are not adequately managed with topi[INVESTIGATOR_15434] -lowering medication for reasons other 
than medication efficacy (eg, due to intolerance or nonadherence) 
Clinical Hypotheses :  
Bimatopro st SR wil l have an IO P-lowering effect that is noninferior to that of SLT in patients with OAG or 
OHT who are not adequately managed with topi[INVESTIGATOR_15434] -lowering medication for reasons other than medication 
efficacy (eg, due to intolerance or nonadherence) .
Bimatopros t SR adminis tered intracamerally will have an acceptable safety profile in patients with OAG or 
OHT who are not adequately managed with topic al IOP -lowering medication for reasons other than medication 
efficacy (eg, due to intolerance or nonadhere nce).
Study Design
Structure:  multicenter, paired eye, randomized, masked , conducted in 2 stages:
Stage 1 :  Bimatoprost SR 15 µg vs SLT; 2administra tion cycles for patients who had not received a 
third administration cycle before implementation of Amendment 3
Stage 2:  Bimatoprost SR 10 µg vs SLT;2 adminis tration cycles
Duration :  approximately 26months, including screening period of up to [ADDRESS_446735] SR 
and SLT administration .
Study Treatment :  Bimatoprost SR 15 µg (Stage 1) or 10 µg (Stage 2)
Controls :  360° SLT adm inistration 
Dosage/Dose Regimen :  
Patients will receive a 360° administration of SLT in [ADDRESS_446736] igator’s discretion during an uns cheduled visit after Week 16 and prior to the Month 12
visit if the retreatment crit eria are met .  (Note that for all patients who were enrolled and reached the Week [ADDRESS_446737] SR was fixed atWeek 16.)In 
order to mask the patient to the treatment assigned to each eye, o nDay 1, a s ham SLT procedure w ill be 
performed in the eye that will receive Bimatoprost SR administrations (hereafter referr edto as the “ Bimatoprost 
SR eye”) .  Similarly, a sham needleless Bimatoprost SR administration (hereafter referred to as the “Sham
Bimatoprost SR administration”) that involves touching the eye at the area of insertion with a needleless 
applicator that do
esnot deliver an implant into the anterior cha mber, will be performed on the SLT -treated eye 
(hereafter referred to as the “SLT ey e”) on Bimat oprost SR administration visits .  
Treatment schedule by [CONTACT_358181]1.
Allergan Confidential Protocol [ADDRESS_446738] SR Eye SLT Eye
SLT administration
(Day  1)Sham SLT 360° SLT
Bimatoprost SR Cycle 1 adm inistration
(Day  4)Bimatoprost SR Sham Bimatoprost SR
Bimatoprost SR Cy cle2 adm inistration
(Week 16)aBimatoprost SR Sham Bimatoprost SR
SLT = selective laser trabeculoplasty; SR = sustained release
aCycle [ADDRESS_446739] SR isperformed at Week 16 for all patients who meet retreatment criteria .  For 
those patients not meeting retreatment criteria at
Week 16, Cycle 2 may be performed at the investigator’s discretion 
during an unsched uled visit a fter Week 16 and prior to the Month 12 visit if the retreatment criteria are met .  
Randomization/Stratification :  The eye with the higher IOP at Baseline wil l be assigned to be the primary eye .  
If baseline IOP is the same in both eyes, the rig ht eye will be the primary eye.  The primary eye will be 
randomized to receive either Bimatoprost SR or SLT using a 1:1 ratio, stratified b y primary eye baseline IOP 
(≤25or > 25 mm Hg)   If the 
primary eye receives Bimatoprost SR, the contralateral 
eye will receive SLT .  If the primary eye receives SLT, 
the contralat eral eye will receive Bimatoprost SR.
Visit Schedule :  Patients w ho complete all study treatments will have up to 28visits and 5 phone calls .  The 
schedule includes the following:
Screening (up to 28 days); Washout period of up to 56 days for both eyes; a nd Baseline visit ( up to 
3days)
SLT treatment (Day 1) and phone call (Day 2) 
Bimatoprost SR Cycle 1 administration (Day 4); Cycle 1 Day 2 safety visit; Cycle 1 Day 4 and Week 2 
phone calls; and follow -up study visits at Weeks 4, 8, 12, and 1 5
Bimatoprost SR Cycle 2 administration (to occur at Week 16 forallpatients who meet retreatment
criteria) ; Cycle 2 Day 2 safety visit; andCycle 2 Day 4 and Week 2 phone calls
oPatients who do not receive Cycle 2 administration at Week 16 will not attend the Cycle 2 
Administration Day visit on Week 16, or the Day 2 Safety or Day 4 and Week 2 phone calls 
associated with administration at Week 16.  For these patients, Cycle 2 may be performed at 
the investigator’s discretion during an unscheduled visit afte r Week 16 and prior to the 
Month 12visit if the retreatment criteria are met ;in this case, inadequate control of IOP 
should be confirmed at another scheduled or unscheduled visit prior to initiation of Cycle 2 .  
All Cycle 2 visits will apply at the time of the Cycle 2 adm inistration .
Follow -up visits at Week s20, 24, 28, 31, 36, 40, 44, 47, and 52 ; and Months 13, 14, 15, 16, 18, 20, 22, 
and 2 4/Exit
oRegardless of the timing of Cycle [ADDRESS_446740] SR at Week 16 and patients 
who never receive a second administration may, at the investigator’s discretion, skip the 

Allergan Confidential Protocol 192024 -093Amendment 7
11 GDD -TA-T-004 v2015.10visits at Months 13, 15 and 22 if the patie nt has receiv ed nonstudy IOP lowering medication 
in both eyes; has ≤ 25% of each implant remaining in the eye; and in the investigator’s 
clinical judgment, has no safety or other concern that would require the patient to attend these 
visits .  Please note : each eye sho uld be evaluated on an individual basis when determining 
the need for additional nonstud y IOP -lowering treatments; initiation of treatment in one eye 
should not automatically lead to initiation of treatment in the contralateral eye.
I
ntraocula r pressure evaluations will occur at Hour 0 (08:00 am ± 1 hour) .  Selected patients at selected 
sites will have additional IOP measurements p erformed at Hour 2 (Hour 0 + 2 hours [± 30 minutes]) 
and Hour 8 (Hour 0
+ 8hours [± 30minutes]) .  
Study Populat ion Characteristics
Number of Patients :  
Stage 1 :  approximately 50 patients
Stage 2 :  approximately 160 patients
Condition/Disease:  patients with OAG or OHT w ho require IOP -lowering medications in both eyes
Key Inclusion Criteria :  
Male or female, 18 years of age or older
Written informed consent and authorization for use and release of personal health information are 
obtained in accordan ce with the relevant country and local privacy requirements, where applicable (eg, 
Written Authorization for Use an d Release of Health and Re search Study Information [[LOCATION_002] 
(US) sites] and written Data Protection consent [European Union (EU) sites] )
In the investigator’s opi[INVESTIGATOR_1649], patient ’s IOP is not adequately managed with topi[INVESTIGATOR_358140] (eg, due to intolerance or nonadherence)
Ocular
In the investigator’s opi[INVESTIGATOR_1649], both eyes can be treated adequately w ith topi[INVESTIGATOR_358141], 
prostaglandin, or prostaglandin analog (eg, LUMIGAN, Xalatan®, Travatan®) eye drops as the sole 
therapy if medication was taken as directed
In the investigator’s o pi[INVESTIGATOR_1649], patient’s IOP can be adequately managed withSLT m onotherapy
In the investigator’s opi[INVESTIGATOR_1649], patient is a suitable candidate for SLT
Diagnosis of either OAG (ie, primary OAG,  pseudoexfolia tion glaucoma, pi[INVESTIGATOR_11232]) or 
OHT in each eye, requ iringbilateral IOP-lowering treatment (Note:  diagnosis does not ha ve to be the 
same in both eyes)
Central endothelial cell density by [CONTACT_358182] d by [CONTACT_358183] 
The iridocorneal angle must be independently confirmed as being qualified by 2 ophthalmologists 
using the following criteria:
Shaffer Grade ≥ 3 on clinical gonioscopy of the inferior angle
Peripher al anterior chamber depth by [CONTACT_358184] ≥ 1/2 corneal thickness 
Note:  The independent eligibility assessments must both agree that the Shaffer grade is ≥ 3 and the 
Van He rick grade is ≥ 1/2 corneal thickness .
Allergan Confidential Protocol 192024 -093Amendment 7
13 GDD -TA-T-004 v2015.10Regulator y Activities (MedDRA) nomenclature.  The number and perce ntage of patients reporting 
treatment -emergent adverse events will be tabulated based on the system organ class and preferred term .  
Ocular safety var
iables attributable to each eye will be tabulated by [CONTACT_358185]. Nonocular 
safety variable s will be summarized.
Sample Size Calculation :  The sam ple size calculation is based on paired -eye differences using a normal 
approximation with a 2-sided significance level of 0.05, assuming that th ere is no dif ference in mean IOP
change from baseline bet ween Bimatoprost SR [ADDRESS_446741] dev iation of 4 mm Hg .  A sample size of 144 patients w ill provide approximately 98% pow er in 
showing no ninfer iority for3out of 3timepoints with a noninferior ity margin of 1.5 mm Hg, and 90% pow er in 
showing noninferiority for 2 out of 3 timepoints with a n oninferiority margin of 1.0 mmHg, assuming that both 
the between -eyes and the within -patient correl ation coeffic ient
sare0.5.  Assuming a premature discont inuation 
rate of 10%, approximately [ADDRESS_446742] SR10µg.  Additionally, there are ap proximately 50 patients who were enrolled before 
implem entatio n
of Ame ndment 3.
Allergan Confidentia l Protocol 192024 -093 Amendment 7
14 GDD -TA-T-004 v2015.10Table 2 Administration Cycle 1 Schedule of Visits and Pr ocedures :  Screening thr ough Day 2
Visit Screening BaselinebDay 1 
(SLT 
Administration)Day 2
Phone 
Callc
Visit Windows Up to 28 days Up to 3 days
Informed Consent/Authorization X
Washouta
Up to 56 daysDem ographic Data X
Medical/Ophthalmic History X X
Adverse Events X X X X
Concomitant Medications/ Procedures X X X X
Visual F unction Questionnaire -25 X
Physical Examinat ion X
Vital Signs (atrest ≥ 5 minutes) X X X
Pregnancy TestdX
Blood and Urine Sample CollectioneXe
Ocular Examinations in bold should be performed in the order shown
Pre-Hour 0 E xam (perform before Hour 0 IOP):
  Macroscopic Conjunc tival HyperemiaAssessmen tfOU
Washouta
Up to [ADDRESS_446743] E xams (may perform in any order at any time before gonioscopy [before Hour 8 at
Baselineh])
  Macroscopic Iris Color Assessment OU
  Visual FieldiOU OU
  Specular Microscopy OU
  Anterior Segment Optical Coherence Tomography OU
Allergan Confidential Protocol [ADDRESS_446744] ty pes:  developmental, 
angle -closure, and open -angle glaucoma (OAG) ( Stamper et al, 2009 ).  Open -angle glaucoma 
is further categorized into primary  OAG (POAG, sometimes a lsoreferred to a schronic 
OAG) and secondary  OAG (which includes pi[INVESTIGATOR_358142]), 
the former being the predominant form of OAG .  Primary  OAG is charac terized as a 
multifactorial optic neuropathy  with a characteristic acquired at
rophy  of the opti cnerve and 
loss of ganglion cells and their axons, developi[INVESTIGATOR_358143] 
(AC) angles, and manifesting characteristic visual field abnormalities 
(American Academ y ofOphthalmolog y,2010a ).  Globa lly, over 60 million people are 
estimated to be affected by  [CONTACT_78541] (the majority  of whom have OAG) and these numbers 
are expected to increase over time ( Quigley  and Broman, 2006; Varma et al, 2011; 
Cook and
Foster, 2012).  Approximately  10% of ey es with elevated intraocular pressure 
(IOP) will progress to OAG over the course of a decade ( Quigley  et al , 1994).
Although man y risk factors have been associated with OAG, elevated IOPremains the mos
t
prominent factor and the only  factor existing that ophthalmic intervention can reliabl y affect 
(Stamper et al, 2009 ).  A number of controlled trials have demonstrated that lowering IOP 
will slow or delay  the appearance or pro gression of g laucomatous da mage.  Large, 
randomized clinical trials such as the Ocular Hy pertension Treatment Study 
(Kass etal,2002) and the Earl y Manifest Glaucoma Trial ( Heijl et al, 2002 ) addresse d the 
value of earl y
detection and lowering of elevated IOP in ocular hy pertension (OHT) or 
POAG .  The effects and parameters of various interventions i n eyes with established 
glaucomatous damage were addressed b y the Collaborative Initial Glaucoma Treatme nt 
Study(Lichter et al, 2001 ) and the Advanced Glaucoma Intervention Study  (AGIS) 
(AGIS, 2000).  The currently  available approaches to lowering IOP include topi[INVESTIGATOR_358144] y, laser trab eculoplast y (LT), incisional surgery , and cy clodestructive 
procedures .  Each of these approaches has its own risk - benefit ratio .  Because the risk- benefit 
ratio with drug therap y appears to be lower than that of surgical procedures, both histo
rical
and con temporary  prac ticehas been to attempt pharmacological treatment before resorting to 
other more invasive alternatives.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
26 GDD -TA-T-004 v 2015.10Although a variet y ofeffective topi[INVESTIGATOR_358145] (including 
bimatoprost) are available, patient n onadh erence t o topi[INVESTIGATOR_358146], as consistent IOP reduction is 
associated with r educed risks of the development and progression of optic nerve damage 
(Friedm an, 2009; Tsai, 2009 ).  One literature review found that up to 80% of patients 
deviated from their prescribed medication regimen ( Olthof f et al, 2005 ) .  In addition, most 
patients with OAG or OHT are elderl y, and many ha ve inherent dif ficulties ap plying daily  
antihy pertensive ey e drops due to phy sical and/or cognitive disabilities such as arthritis and 
poor memory  (European Glaucoma Societ y guidelines, 2014 ; Tsai, 2009 ) .  Guidelines have 
been developed a nd provided to clinicians for assisting patients with being adherent
(Budenz, 2009).  In addition, surgical i nterventions, both laser based (eg, LT) and incisional, 
are recommended as treatment options for patien
ts with OAG a nd OHT who have challenges 
with topi[INVESTIGATOR_78505] ( European Glaucoma Society  guidelines, 
2014).  Laser trabeculoplasty is a safe and noninvasive procedure; however, repeatability  of 
LT is controversial ( Realini, 20 08).  Patients will often require adjunctive therap y after LT, 
and may  eventually  requir e incisional surgery  to control their IOP 
(Francis et al, 2005; 
Koucheki and Hashemi, 2012 ).  Incisional surgery  present s the risk of si gnificant 
sight -
threatening complications, such as the globe perforation, suprachoroidal hemorrhage, 
hypotony  maculopathy , corneal decompensation, and cataract formation or progression that 
may occur 
with filtering surgery  (Mo saedet al, 2009).  As a result, Allergan has developed a 
sustained -release (SR) bimatoprost implant as an ocular antih ypertensive therap y for patients 
with OAG and OHT who are not adequatel y managed by [CONTACT_12523][INVESTIGATOR_358147] t o 
medication a dherence or to lerability  issues.
1.[ADDRESS_446745] (LUMIGAN®)
Bimatoprost is a member of a series of unique prostanoid compounds that are potent and 
efficacious ocular antih ypertensive agents (Woodward et al, 1994, 2 001, and 2004).  
Bimatoprost appears to mimic the activity  of biologically  active prostamides 
(Study BIO
-99-308; Matias et al, 2004 ).  Chemically , prostamides differ from prostaglandin 
analog s by [CONTACT_358186] l because they lac
k carboxy lic acids ( Krauss and Woodward, 2004 ).  
Prostamides can be bios ynthetically derived from anandamide, an endogenous membrane 
lipid ( Kozak et al, 2002 ; Weber et al, 200 4; Woodward e t al, 2001; Yu et al, 1997 ).  The
prostamide pathway  leads to the biosy nthesis of novel lipid amides that lower IOP.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
27 GDD -TA-T-004 v 2015.10The IOP -lowering efficacy of LUMIGAN (bimatoprost ophthalmic solution) 0.0 3% is well 
establi shed.  In phas e 3 studies in patients with POAG or OHT, LUMIGAN administered 
once dail y as monotherapy was superior to timolol at all timepoints 
(Higginbotham etal,2002).  This was further substantiated i n the extens ion stu dies which 
followed patients in a masked manner for up to 4 y ears ( Cohen et al, 2004; 
Williams etal,2008 ; Study 192024- 014).  In clinical studies of patients with OAG or OHT 
with a mean baseline IOP of 26mmHg, the IOP-lowering effect o f LUMIGAN administered 
once dail y in the evening was 7 to 8 mmHg (Cohen et al, 2004; 
LUM IGAN®Package Insert, 2012; Williams et al, 2008 ) .  LUMIGAN was approved b y the 
[LOCATION_002] (US) F ood and Drug Adminis tration (FDA) in 2001.  Worldwide, L UMIGAN 
0.03% is currentl y licensed and 
marketed in more than 80 countries and LUMI GAN 0.01% is 
licensed and marketed in more than [ADDRESS_446746] ophthalmic 
solution 0.03% has been approved s ince November 2012 for lowering IOP, and is currentl y 
marketed in 10 countr ies.  
A sustained -release (SR) formulation of bimatoprost was developed at Allergan, Inc. to 
evaluate ocular antih
ypertensive therapi[INVESTIGATOR_358148] -admini stration.  
Bimatopr ost SR refers to the biodegradable, sustained -release, preser vative -
free bimatoprost 
implant which is preloaded in an applicator for administration; together they comprise the 
Bimatoprost SR product .  The Bimatoprost SR implant is inject ed in tothe AC via th e corneal 
limbus using the prefilled applicator .  The biode gradable pol ymer matrix graduall y degrades 
to carbon dioxide and water so that there is no need to remove the Bimatoprost SR implant 
once the drug has been relea sed.  The Bimat opros t SR implant u sed in this study contains a 
total preservative -free bimatopr ost load of 1 0μg, and intracameral administration of this dose 
strength is expected to reduce the total dail y drug exposure to the eye b y approximately  
126-foldcompared with topic alLUMIGAN 0.0 3%application over [ADDRESS_446747] SR implant exceeds the drug release duration, 
experience from preclinical studies, the phase 1/2 (Study  192024-041D), and approved 
intravitreal impl ants 
composed of si milar biodegradable polymers provide support for the
anticipa ted safety  in a phase [ADDRESS_446748] SR
Pharmacology , toxicology , and pharmacokinetic stud ies with multip le dose strengths, implant 
sizes, and formulations (Generation 1 and Generation 2) of Bimatoprost SR were completed 

Allergan Confidential Protocol 192024 -093 Ame ndment 7
28 GDD -TA-T-004 v 2015.10in 2 species (Beagle dogs and Cy nomolgus monkey s) with a range of AC angle sizes in order 
to support the clinical program .  These studies bu ild on the alread y considerable amount of 
nonclinical and clinical information a vailable for topi[INVESTIGATOR_358149] (see Investigator’s 
Brochure [IB] for additional details).
Nonclinical studies with pharmacology  endpoints (Reports BIO -
09-803, BIO-11-920, 
PK0
9109- PK, BIO -09-785) showed dose -related reductions in IOP in normotensive 
Cynomolgus monkey s and Beagle dogs, as well as in laser -induced ocular hy pertensive 
Cynomolgus monkey s following single doses .  Toxicology  studies, of at least [ADDRESS_446749] SR administration, were conducted in 
Cynomolgus monkey s and Beagle dogs (Studies TX09051 -TX, TX09066
-TX, TX10016- TX, 
TX11076- TX, TX12012 -TX, TX12018- TX, and TX12102- TX).  Monkey s, which have a 
characteristical ly small AC angle c om
pared to both dogs and humans, did not tolerate 
Bimatoprost SR dose strengths tested ( ≥ [ADDRESS_446750] SR) due to chronic contact [CONTACT_358187].  Single and repeat ocular toxicity  studies with Generation 
[ADDRESS_446751] SR in dogs with vary ing AC angle sizes demonstrated acceptable safet y and 
ocular tolerability  with single doses ≤ 20 μg  (Studies TX11076- TX, TX12012 -TX, 
TX12018- TX) and with repeat doses of ≤ 15 μg (Studies TX12012 -TX and TX12018- TX).  
Furthermore, no adverse drug -
or implant-related ocular findings have been seen followin g 
3intracameral injections of up to 20 μg (two 1 0 μg implants) Bimatoprost SR in the 
18-month repeat -dose Good L aboratory  Practice (GL P) study  in dogs (Study TX12102 -TX) .  
Pharmacokinetic studies of Bimatoprost SR (Studies PK09109 -PK and PK11086 -PK) in 
Beagle dogs demonstrated that sy stemic exposure of bimatoprost and bimatoprost acid was 
below the limit of quantitation (BLQ) with doses ≤ 60 μg.  Aqueous humor concentrations 
generall y peaked b y 10 weeks postdose for doses  
μg (Generation 1 and Generat ion 2), 
then declined to low levels suggestive of near -complete drug release from the device at  
months for doses  μg.  By  14 weeks following a 20 μg (Generation 2) dose, ocular 
tissues samples were collected for anal ysis, which demonstrated t hat drug and metabolite 
concentrations were BLQ in aqueous humor, vitreous humor, retina, and the remnant 
implants, but detected in cornea, choroid, and iris -ciliary  body .  A pharmacokinetic study  
(PK14025
-PK) was conducted in Beagle dogs comparing the ocu lar dist ribution of topi[INVESTIGATOR_358150] 0.03% solution or a single Generation [ADDRESS_446752] SR implant (15 µg) .  
Following topi[INVESTIGATOR_78086], bimatoprost and bimatoprost acid distributed into the 
iris-ciliary  body  as well as other (off target) tissues with concentrations in the bulbar 
conjunctiva, ey elid margin, and periorbital fat significantly  higher than those observed in the 
iris-ciliary  body .  In contrast, following administration of a single Generation [ADDRESS_446753] acid concentrations were either below the 

Allergan Confidential Protocol 192024 -093 Ame ndment 7
29 GDD -TA-T-004 v 2015.10limit of quantitation (BLQ) or near the detection limit in bulbar conjunctiva, ey elid margin, 
and periorbital fat while the highest bimatoprost and bimatoprost acid concentrations were 
observed i n the ta rget tissue, the iris ciliary  body .  Retinal concentrations were BLQ 
following both topi[INVESTIGATOR_358151].
1.2.2 Other Biodegradable Ocular Implants
A number of SR drug delivery implants using the Allergan pol ylactic acid (PL A) and/or
polylactic-co-glycolic acid (PL GA) biodegradable platform preceded the development of the 
Bimatoprost SR implant .  The extensive clinical experience with previous intraocular 
implants demonstrates the safet y and tolerability  of an intraocular biodegradabl e implan t 
administered into the ey e via an applicator s ystem.  For example, late phase clinical trials of 
SR implants have been completed for the OZURDEX®dexamethasone intravitreal implant 
using the NOVADUR® drug delivery  system for intraocular injections.  Becau se Bimatoprost 
SR is similar to OZURDEX in a number of aspects and uses the NOVADUR drug delivery  
system for intraocular injections, these data may  be supportive of the safet y and tolerability 
of Bimatoprost SR in humans.
1.2.3 Clinical S tudies with Bim atopr ostSR
Study 192024 -041D was a phase 1/[ADDRESS_446754] SR (6, 10, 15, or 20 μg [2 x10 μg implants]), as 
single or repeat administrations in 1 ey e (study  eye), versus the use of topi[INVESTIGATOR_2855] L UMIGAN
0.03% once daily  in the contralateral eye (nonstudy  eye).  The objective of this study  was to 
evaluate the safet y and IOP -lowering efficacy  of Bimatopr ost SR in patients with OAG .  
A
total of [ADDRESS_446755] patients (> 66%) were still maintained on monotherap y with the initial 
Bimatoprost SR implant administered .  Among all Generation [ADDRESS_446756] 33% 
of patients had not received rescue or a second Bimatoprost SR treatment by  [CONTACT_43380] [ADDRESS_446757] 23% of patients had not received rescue or a second treatment .  
Allergan Confidential Protocol [ADDRESS_446758] SR administration, and were considered 
related to the stud y drug administration procedure .  There were no reports of serious study  
drug-
related adverse events, and no new safet y concerns were observe d after the second 
treatment .  Please refer to the Investigator ’s Brochure for details on reported safet y findings .
Two identical global phase 3 studies (Studies 192024- 091 and 192024 -092) were initiated in 
late 2014.  These studies are assessing the safety  and ef ficacy  of Bimatoprost SR in 
multicenter , randomized, masked, parallel- group comparison studies of [ADDRESS_446759] SR (10 and 15 µg) to an active control (timolol maleate 0.5%).
1.3 Study Rationale
Results of the completed phase 1/[ADDRESS_446760] SR 
at dose strengths of 20 μg (2 × 10 μg) or less in the phase 1/[ADDRESS_446761] SR in 
patients with OAG or OHT who are not adequately  managed with topi[INVESTIGATOR_73201] (eg, 
due to intolerance or nonadherence).  
Based on the interim data from phase 1/[ADDRESS_446762] an SL T comparator (192024 -093 and 192024- 095).  After
additional data from later
-stage studies became available ,the proto col in one of these studies 
(192024- 093) wasamended (Amendment 3) to reduce the dose strength for newly  enrolled 
patients to 10 µg,in order to broaden the range of dose strengths evaluated in the 2 phase 3 
studies with the SLT comparator arm.  In additio n, the number of administration cycleswas 
reduced from 3 to 2 (eliminating Week 32 administration for newl y enrolled patients and 
ongoing patients who ha dnot y et received the Week 32 administration).  The number of 
administration cy cles was reduced based on the duration of effect observed in completed 
24-month Study [ADDRESS_446763] 3 months of 
treatment (primary  anal ysis) in Study 192024-091, which suggested that the majority  of 
patients do not require rescue tre atment for an extended duration following their last 
Bimatoprost SR admin istration .  The results of both studies suggest that efficacy  may be 
Allergan Confidential Protocol [ADDRESS_446764] SR at 
Week 16 ( patients not me eting retreatment criteria at Week [ADDRESS_446765] SR at the investigator’s discretion during an unscheduled visit 
after Week 16 an d prior to the Month 12 visit if the retreatment criteria are met).  Th echange 
from [ADDRESS_446766] y (SLT), which is also indicated for this patient population .  SLT, one of the 
most frequently  used L T modalities, is commonly  used as an intermediate step between 
topi[INVESTIGATOR_358152] y (AL
T) (Damji et al, 1999; Damji etal,2006; 
Martinez -de-la-casa et al, 2004; Rolim de Moura et al, 2007; Wanget al, 2013 ).  SL T causes
minimal tissue destruction compared with ALT and is increasingly  being adopted as the L T 
standard of care ( Realini, 2008 ).  SL T has been reported to reduce IOP  effectively  in ey es 
with OHT  and OAG , as reports often suggest IOP reduction to be similar to topi[INVESTIGATOR_358153] ( Katz et al, 2012; Nagar et al, 2009; McAlinden 2014 ) .  This study  
is [ADDRESS_446767] SR compared with SL T in 
patients with OAG or OHT ,who are not adequately  managed with topi[INVESTIGATOR_15434] -lowering 
medica tion for reasons other than medication ef ficacy  (eg, due to intolerance or 
nonadherence).
2.[ADDRESS_446768] that is noninferior to that of SL T in patients 
with OAG or OHT  who are not adequatel y managed with topi[INVESTIGATOR_15434] -lowering medication 
for reasons other than medication ef ficacy  (eg, due to intolerance or nonadherence).
Allergan Confidential Protocol [ADDRESS_446769] an acceptable safet y profile in patients 
with OAG or OHT  who are not adequatel y manag edwith topi[INVESTIGATOR_15434] -lowering medication
for reasons other than medication ef ficacy (eg, due to intolerance or nonadherence).
3. Study Design
This study  is a multicenter, paired -eye, randomized, efficacy evaluator -masked 26-mon th 
study conducted in [ADDRESS_446770] SR 
(Stage 1:  15µg; Stage 2:  10 µg) .  The safet y and IOP-lowering effect of Bimatoprost SR 
will be compared with SLT in OAG and OHT patients who are not adequately  managed with 
topi[INVESTIGATOR_358154] (eg, due to intolerance or 
nonadherence).
The study  is being conducted in 2 stages because the protocol was amended (Amendment 3)
to reduce the dose strength for newl y enrolled patients to [ADDRESS_446771] SR or SLT using a 1:1 ratio, s tratified by  [CONTACT_358188] ( ≤ 25 versus > 25 mm Hg)  
  If the primary  eye receives Bimatoprost SR, the 
contralateral ey e will receive SL T.  If theprimary ey e receives SLT , the contralateral ey e 
will receive Bimatoprost SR.
Patients will receive a 360° administration of SL T in [ADDRESS_446772] SR at 
Week 16 forallpatient s who meet retreatment criteria .  For those patients 
not meeting retreatment criteria at Week 16, Cy cle 2 may  be performed at the investigator’s 
discretion during an unscheduled visit after Week 16 and prior to the Month 12 visit if the 
retreatment criteria are met .  (Note that for all patients who were enrolled and reached the 
Week [ADDRESS_446773] SR 
was fixed at Week 16.) In order to mask the patient to the treatment assigned to ea ch ey e, on 
Day [ADDRESS_446774] 
SR(hereafter refer to as the “ Bimatoprost SR ey e”).  A S ham Bimatoprost SR administration 
will be performed in the ey ethat underwent SLT (here after refer redto as the “SLT ey e”) on 
each Bimatoprost SR administration visit
(Day  4 and Week 16) (see 

Allergan Confidential Protocol 192024 -093 Ame ndment 7
33 GDD -TA-T-004 v 2015.10Table 1).
4. Study Population and Entry Criteria
4.[ADDRESS_446775] 
SR 10µg complete the study  based on a premature discontinuation rate of 10% .  
Approximately  [ADDRESS_446776] SR 1 5µg.
4.2 Study Population Character istics
The study  population consists of patients with bilateral OAG or OHT
 who are not adequatel y 
managed with topi[INVESTIGATOR_358155] (eg, d ue to 
intolerance or nonadherence) .  Both ey es must require IOP -lowering treatment, must be able 
to be 
adequately  managed on SL T monotherapy , and must meet study  entry criteria.
4.2.1 Patients with Sick le Cell Trait/Disease or  Other 
Hemoglobinopathies
Patients w ith sickle cell trait or disease or o ther hemoglobinopathies may  be enrolled at the 
discretion of the investigator based on an individual risk- benefit assessment .  Because of a 
slightly  higher risk of IOP  elevation and intraocular complications in the sett
ing of a 
microhy phema, patients with these disorders may  undergo optional additional safet y 
monitoring (biomicroscopy  and IOP measurement) after Bimatoprost SR administration at 
the investigator ’s discretion.  Additional information about the previous experience with the 
use of Bimatoprost SR in patients with sickle cell trait is provided in the IB .  
4.3 Inclusion Criteria
The following are requirements for entry  into the study :  
1.Male or female, 18 years of age or older 
Allergan Confidential Protocol 192024 -093 Ame ndment 7
34 GDD -TA-T-004 v 2015.102.Written informed consent and authoriz ation for use and release of personal health 
information are obtained in accordance with the relevant country  and local privacy  
requirements, where applicable (eg, W ritten Authorization for Use and Release of 
Health and Research Study Information [Unites S tates (US) sites] and written Data 
Protection consent [European Union (EU) sites])
3.Patient is willing to withhold his/her IOP  treatments according to the study  
requirements, and in the opi[INVESTIGATOR_871] , can do so without significant 
risk.  Note: If patients cannot discontinue their currentl y prescribed therapy for up to 
8weeks to meet the W ashout period for study  entry , the investigator may  switch the 
patient’ s medication to one that requires a shorter washout interval during the 
washout of the original medication (see Sec tion 8.2and Table7)
4.Patient has the abil
ity to understand and the willingness to follow study  instructions 
and requirements and is likely  to complete all required visits and procedures
5.In the investigator ’s opi[INVESTIGATOR_1649], patient’ s IOP  is not 
adequatel y managed with topi[INVESTIGATOR_358156]  (eg, due to intolerance or 
nonadherence)
6.Negative pregnancy  test at Baseline for females of childbearing potential
Ocular Inclusion Criteria for Both Ey es:
7.In the investigator ’s opi[INVESTIGATOR_1649], both ey escan be treated adequately  with topi[INVESTIGATOR_78507], prostaglandin, or prostaglandin analog (eg, LUMIGAN, Xalatan, 
Travatan) ey e drops as the sole therap y if medication was taken as directed
8.In the investigator ’s opi[INVESTIGATOR_1649], patient’ s IOP  can be adeq uatel y managed with SL T 
monotherap y
9.In the investigator ’s opi[INVESTIGATOR_1649], patient is a suitable candidate for SL T
10. Diagnosis of either OAG (ie, prim ary OAG , pseudoexfoliation glaucoma, pi[INVESTIGATOR_358157]) or OHT  in each eye, requiring bilateral IOP -lowering treat ment .  (Note :  
diagnosis does not have to be the same in both ey es)
11.Central endothelial cell density  by [CONTACT_358189] b e
ing qualified 
by [CONTACT_358190] W ashout 
12.The iridocorneal angle must be independentl y confirmed as being qualified by  2 
ophthalmologists using the following criteria:
a.Shaffer Grade ≥ 3 on clinical gonioscop y of the inferior a ngle
b.Peripheral anterior chamber depth b y Van Herick examination ≥ 1/2 corneal 
thickness 
Allergan Confidential Protocol 192024 -093 Ame ndment 7
35 GDD -TA-T-004 v 2015.10Note :  The independent eligi bility  assessments must both agree that the Shaf fer grade 
is ≥3 and the V an Herick grade is ≥ 1/2 corneal thickness  
13.At the Baseline visit, patient has been appropriately washed out of all IOP -lowering 
medications
14.
At the Baseline visit (8:00 am ± 1 hour) , IOP  of ≥22 and ≤34 mm Hg, with 
difference between eyes of ≤5 mm Hg  
15.At the Screening and Baseline (Day  -3 to -1) visits, Best -Corrected Visual Acuity  
(Snellen equivalent, b y manifest refraction) of 20/ 50 or better in each ey e
4.4 Exclusion Criteria
The following are criteria for exclusion from participating in the stud y:
1.Uncontroll e
d systemic disease
2. Females who are pregnant, nursing, or planning a pregnancy , or who are of 
childbearing potential and not using a reliable means of contraceptio n during the 
study  (see Section 4.5.3)
3.Known all ergy or sensitivity  to the study  medication or its components, any  
component of the delivery  vehicl
e, or any diagnostic or surgical prep agents used 
during the stud y (eg, topi[INVESTIGATOR_15413], dilating drops, fluorescein , povidone -iodine )
4.Any condition which would preclude the patient’ s ability  to comply  with study  
requirements (including completion of th e study )
5.Patients who have a condition or are in a situation, which, in the investigator ’s 
opi[INVESTIGATOR_1649], may  put the patient at significant risk, may  confound the study  results, or 
may interfere significantly  with the patient’ s participation in the study
6.Concur rent or anticipated enrollment in an investigational drug or device study  or 
participation in such a study  from [ADDRESS_446777] SR; c oncurrent enrollment in 
another Allergan Bimatoprost SR study ; or previous enrollment in which an implant 
was received.  Patients enrolled in the 192024 -091/092 studies who were r andomized 
to the control treatment and never received an implant may  be considered for 
enrollment at the investigator ’s discretion.  
8.Known history  of bleeding disorder or prolonged bleeding after surgery  (in the 
opi[INVESTIGATOR_871]).  Note :  Patients receiving pharmacologic blood thinners 
(eg, aspi[INVESTIGATOR_248], Coumadin) may
 be enrolled at the investig ator’s discretion.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
36 GDD -TA-T-004 v 2015.10Ocular Exclusion Criteria for Both Ey es:
9.History  of previous laser trabeculoplast y
10.History  or evidence of clinically  relevant, substantia l ocular trauma (eg, a traumatic 
cataract, traumatic angle recession, etc)
11.The following surgical hi story :
a.History  or evidence of complicated cataract surgery :  eg, surgery 
resulting in complicated lens placement (such as anterior chamber 
intraocular lens im plant [IOL ], sulcus IOL, aphakia , etc) or 
intraoperative complications (such as a posterior capsul ar tear [with or 
without vitreous loss], substantial iris trauma, etc) .  
Note :  history  of uncomplicated cataract surgery is not an exclusion.
b.History  of phakic IOL  insertion for refractive error correction 
12.Intraocular surgery (including cataract surgery) and/or any ocular laser surgery within 
the 6 months prior to treatment (Day  1) 
13.Any history  of corneal graft, including partial grafts (eg, De scemet’ s Strippi[INVESTIGATOR_358158] y [DSEK], Descemet’ s Membrane Endothelial Keratoplasty  
[DMEK]); or incisional refractive surgery (eg, radial keratotomy), other than 
astigmatic keratotomy  or limbal relaxing incisions
14. Corneal or other ocular abnormalities that w ould preclude accurate readings with an 
applanation tonometer , anterior segment- optical coherence tomography , specular 
microscope, and/or a contact [CONTACT_358191], or could confound study  results, eg, 
moderate to severe corneal dy strophy , including Anterior Ba sement Membrane 
Disease (ABMD; ie, Map- Dot-Fingerprint [MDF]) and guttata .  Mild ABMD or mild 
guttata are not exclusionary  by [CONTACT_78551], in the opi[INVESTIGATOR_1070] , the condition is stable and not likely  to cause corneal changes dur
ing the 
course of the stud y
.  
15. Active or recurrent ocular disease (eg, uveitis, ocular infection, chronic moderate to 
severe blepharitis or severe dry  eye, severe ocular seasonal allergies) or sight 
threatening diseases (eg, neovascular age -related macular degeneration [ARMD], 
diabetic macular edema) that, in the opi[INVESTIGATOR_871] , would put the patient 
at a significant risk or would interfere with the interpretation of the stud y data .  
Patients with slowly  progressive ey e diseases (ie, mild catar a
cts, nonneovascular 
ARMD) can be enrolled at the discretion of the investigator.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
37 GDD -TA-T-004 v 2015.1016.Any history  of external ocular or intraocular malignancy , and/or any  history of benign 
ocular neoplasia that in the investigator ’s opi[INVESTIGATOR_358159]  
17.History  of herpetic ocular diseases (including herpes simplex virus and varicella 
zoster virus)
18.The following ocular surface findings:
a.Bulbar conjunctival h yperemia ,on either macroscopic or slit -lamp 
examination, > +1
(mild) at baseline
b. Active ocular surface findings other than bulbar conjunctival 
hyperemia, on either macroscopic or slit- lamp examination, > + 1
(mild) at Baseline
19.History  of moderate or worse ( ≥ +2) bulbar conjunctival hy peremia due to marketed 
prost aglandin, prostamide, or prostaglandin analog use
20.
The anticipated wearing of contact [CONTACT_358192] (contact [CONTACT_78552] , but is to be temporarily  
discontinued before study visits, and bef ore and after an Administr ation Day  
according to the following) :
a.Use of soft lenses should be discontinued at least [ADDRESS_446778] SR (or Sham) administration
21. Central corneal thickness of < 480 or > 620 micrometers 
22.Anticipated need for an y incisional or laser ocular sur gery during the study
23.History  of anatomicall y narrow angle resulting in evidence of angle chan ges or an y 
history  of closed angle glaucoma .  Note :  historically  narrow angled patients whose 
angle has been opened by [CONTACT_358193] a ngle abnormalities.
24.History  or ev i d ence of a peripheral iridotomy /iridectomy  in the inferior iris 
Allergan Confidential Protocol 192024 -093 Ame ndment 7
38 GDD -TA-T-004 v 2015.1025.Any history  of trabeculectomy  or other t ypes of glaucoma surgery , including a 
glaucoma seton or aqueous by [CONTACT_78554]
26.Peripheral anterior s ynechiae (P AS) in the inferior iridocorneal angle o ngonioscopic 
examination at Screening
27.Visual field loss that, in the opi[INVESTIGATOR_871] , is functionally  significant (eg, 
split fixation, field defect within the central 10 degrees that is visually  significant or 
likely  to cause central visual impairment upon progression) or shows evidence of 
progressive visual field loss within the y ear prior to baseline (Note :  Two visual fields 
are required for qualification, 1 performed within the 10 months prior to or at 
Scree ning, and 1 performed at baseline or during the washout period using the 
protocol -required testing method [see Procedure Manual] .  The same test 
methodology  should be used for all historical and study -related examination for a 
given patient.)
28.Evidence of m acular edema during screening or inpatient’ s medical history  
29.Anticipated use of corticosteroids in either ey e (except as described in Section 4.5.1
[Permissible Medications/T reatments]) or s ystemically  during the study , or historical 
use prior to Baseline within:
3 years:  intraocular fluocinolone acetonide
6 months:  intraocular corticosteroid(s) other than fluocinolone; an y injectable 
periocular or sub -Tenon’s/subconjunctival corticosteroid
2 months:  systemic (eg, oral, intramuscular , intra venous) or topi[INVESTIGATOR_78510] 
2 weeks :  dermal corticosteroids applied to skin of the ey elid(s), around the ey e, 
or adnexa 
30.Anticipated use of other topi[INVESTIGATOR_358160] 4.5.1 (Permissible Medications/T reatments)
4.5 Permissible and Prohibited Medications/T reatments
4.5.1
Permissible Medications/T reatments
Ophthalmic Medications/T reatments
Intermittent use of artificial tear products is allowed if they  are taken > 15 minute sbefore an y 
study  procedure or if they  are required for a study procedure .  Intermittent use of ocular 
decongestants or antihistamines is allowed if not taken within 2 days prior to a scheduled 
visit.  
Allergan Confidential Protocol 192024 -093 Ame ndment 7
39 GDD -TA-T-004 v 2015.10Use of artificial tear products and ocular decongestan ts or antihistamines may  be restarted 
3days after any  study  administration (Bimatoprost SR, Sham Bimatoprost SR, SL T, or Sham 
SLT) procedure .  
Note :  post-procedural use of artificial tear products following SL T/Sham SL T 
administration is allowed at th
einvestigator ’s discretion; patients should be instructed 
to wait at least 15 -20 minutes after instilling required medication (eg, NSAID) drops 
before instilling artificial tear products.  Use of artificial tears is not allowed 
following B imatoprost SR/Sh a
mBimatoprost SR administration except as described 
above (restart 3 day s after).
Use of post -Bimatoprost SR administration topi[INVESTIGATOR_358161] 3 days, and 
corticosteroids or nonsteroidal anti -inflammatory  drugs (NSAIDs) for up to [ADDRESS_446779] -SLT topi[INVESTIGATOR_358162] (ie, 
brimonidine or apraclonidine) is permissible
.  Post -SLT topi[INVESTIGATOR_358163] [ADDRESS_446780] -SLT are 
described in detail in Section 5.9.2 .
Systemic Medications
Systemic beta -blocker containing medications are permitted, provided that the dose/dosing 
regim en has remained stable for at least 2 months prior to screening and is not anticipated to 
change during the duration of the study .
The use of s ystemic NSAIDS is also permitted.
In addition, therap y considered necessary  for the patient’ s welfare may  be give nat the 
discretion of the investigator .  If possible, the concurrent therap y (ocular and sy stemic) 
administered should not have an ef fect on study  outcomes.  However , if concurrent 
medications may  have an ef fect on study  outcomes, these medications should be 
administered in dosages that remain constant throughout the duration of the study .  If the 
permissibility  of a specific medication/treatment is in question, please contact [CONTACT_78562] .      
In the unlikel y event that the Bimatoprost SR implant requires r
emoval for significant safet y 
reasons, this may  be performed at the discretion of the investigator following a discussion 
with the medical safety  physician at Allergan as needed (see Procedure Manual for details).
Allergan Confidential Protocol [ADDRESS_446781] SR implanted ey e during which ocular fluid is to be removed, 
ocular fluid/implant samples may  be collected for anal ysisat the investigator ’s discretion 
(see Procedure Manual for details).
4.5.2 Prohibited Medications/T reatments
The decision to administer a prohibited medication/treatment is taken with the safet y of the 
study  participant as the primary  consideration
.  When possible, Allergan should be notified 
before the prohibited med ication/treatment is administered.
During the study , patients must not participate in other investigational drug or device studies.
Nonstudy  IOP-lowering Treatments
Any concurrent nonstudy IOP -lowering treatment (eg, topi[INVESTIGATOR_358164], L T) is prohibited in either ey e during the stud y 
(through Month 24), unless necessary  for the safety  of the patient due to inadequate control 
of IOP  as determined b y the investigator.  Inadequate control o f IOP  should be confi rmed at a 
subsequent visit (scheduled or unscheduled visit).  Initiation of treatment in one ey e should 
not automatically  lead to initiation of treatment in the contralateral eye .  Each ey e should be 
evaluated on an individual basis wh en determining the ne edfor additional nonstudy  IOP-
lowering treatment s.  If nonstudy  IOP-lowering treatment is initiated, the investigator will be 
expected to attest to the need for additional nonstudy  IOP-lowering treatment for safet y 
reasons for each ey e individually . Use ofany concurrent nonstud y IOP-lowering treatment 
with any  known effect on study  outcomes (eg, crossover ef fect on the contralateral ey e) is 
prohibited during the study .  
In order to maintain patient masking to treatments assigned to each ey e, patien ts wh
o have 
received nonstudy  topi[INVESTIGATOR_2855] I OP-lowering treatment in a Bimatoprost SR ey e will receive 
Sham Bimatoprost SR administration in that ey e on the Bimatoprost SR Cycle 2 
administration day (s).  If nonstudy  topi[INVESTIGATOR_15434] -lowering medicati on is initiated in an SLT 
eye, the patient will continue to receive Sham Bimatoprost SR administration in the SL T eye 
on the administration day(s) .  In all cases, the contralateral ey e that does not require nonstudy  
topi[INVESTIGATOR_15434] -lowering medication will maintain the same t reatm entregimen assigned at 
randomization
.  Patients who have received nonstudy IOP -lowering treatment in both ey es 
will not receive Bimatoprost SR administration or Sham Bimatoprost SR administration in 
either ey e, and therefore do not ne ed to attend theBima toprost SR (or Sham Bimatoprost SR) 
administration visits and immediate postadministration visits ( ie, Bimatoprost SR Cy cle 2 
Allergan Confidential Protocol 192024 -093 Ame ndment 7
41 GDD -TA-T-004 v 2015.10administration [W eek 16], Cy cle 2 Day  2 safet y visit, and Cycle 2 Day  4 and Week 2 phone 
calls).
Contact [CONTACT_358194] c ontac t lenses within [ADDRESS_446782] SR (or Sham ) administration in either 
eye is prohibited .  
Other Medications
The following medications (or classes of medications) and treatment procedures are not 
permitted as concurrent therap y during the stud y unless the patient has already  received 
nonstudy  IOP-lowering medicati on or tr eatment in both ey es:
Subconjunctival, sub -Tenon’s, intravitreal, or other ophthalmic injections of any  
medications in either ey e
Use of an y topi[INVESTIGATOR_20718] (except as described above and in 
Section 4.5.1 ) in either eye
Surgical (incisional and laser) procedures that are not related to study -specific 
Bimatoprost SR (or Sham) and SL T administration procedures in either ey e; patients 
may exit th e study  early if an ophthalmic incisional proced ure is required  
Oral, intramuscular , or intravenous corticosteroids from 2 months prior to the 
Baseline visit through study  exit 
Use of bimatoprost for hypotrichosis during the study  period in either ey e
Use of cyclosporine ophthalmic solution during th e study period in either ey e
Systemic use of carbonic anhy drase inhibitor 
Any initiation of or alterations in sy stemic regimen of beta -blocker containing 
medications from 2 months prior to screening through the study  exit
Use of corticosteroids in either eye (except as described in Section 4.5.1 for 
postoperative use) or s ystemically  during the study o r historical use prior to Baseline 
within:
Allergan Confidential Protocol 192024 -093 Ame ndment 7
42 GDD -TA-T-004 v 2015.103 years:  intraocular fluocinolone acetonide
6 months:  intraocular c orticosteroid(s) other than fluocinolone; an y injectable 
periocular or sub
-Tenon’s/subconjunctival corticosteroid
2 months:  systemic (eg, oral, intramuscular , intravenous) or topi[INVESTIGATOR_78510] 
2 weeks :  dermal corticosteroid applied to skin of the e yelid(s), around the eye, or 
adnexa
4.5.3 Definition of Females of (Non -)Childbearing Potential and/or 
Acceptable Contraceptive Methods
For pu rposes of this study , females will be considered of childbearing potential unless they  
are naturall y postmenopausal or permanently  sterilized (ie, hy sterectom y).  Natural 
menopause is defined as the permanent cessation of menstrual periods, determined 
retrospectivel y after a woman has experienced 12 months of amenorrhea without any  other 
obvious pathological or phy siolog ical cause .  For women of childbearing potential who may  
participate in the study , the following methods of contraception, if properl y used , are 
generall y considered reliable :  hormonal contraceptives (ie, oral, patch, injection, implant), 
male condom with intravaginal spermicide, diaphragm or cervical cap with spermicide, 
vaginal contraceptive ring, intrauterine device, surgical sterilizatio n (bilateral tubal ligation, 
bilateral salpi[INVESTIGATOR_8820] y), vasectomized partner , or true sexual abstinence (when thi s is i
nline 
with the preferred and usual lifesty le of the subject).
The investigator and each patient will determine the appropriate method of contraception for 
the patient during the participation in the study .
If a female becomes pregnant during the stu dy, the investigator will notify  Allergan 
immediately
 after the pregnancy  is confirmed and the patient will be exited from the study  
after appropriate safety  follow up .  The investigator will (1) notify  the patient’ s phy sician that 
the patient was being tr eated with an investigational drug ( and unmask the study  treatment as 
needed for pregnancy  monitoring ), and (2) follow the progress of the pregn ancy.  The 
investigator must document the outcome of the pregnancy  and provide a copy  of the 
documentation to Allerga n.
Allergan Confidential Protocol [ADDRESS_446783] di spersed 
in a biodegradable polymer matrix (including PLA  and PL GA).  The biodegradable implants 
are preloaded in the applicator .  The formulation sused in this study  are Bimatoprost SR 
15µg (11048X , for Stage 1
) and 10 µg (1 1047X , for Stage 2 ).
5.2 Contr ol Treatment 
The control treatment is a 360° administration of SL T.
5.[ADDRESS_446784] SR administration involves touching of the ey e at the 
area of insertion with an Aller g
an-provided needleless applicator that does not deliv er an 
implant into the AC.  
The patient and the site staf f will be masked to the treatment assignment for each ey e
.  Only 
the site coordinator and designated staff will be unmasked to the patient’ s treatment 
assignment for each ey e.  Efficacy  IOP measurem ents will be masked using a [ADDRESS_446785] SR administration (eg, topi[INVESTIGATOR_95610] -inflammatory  eyedrops) or 
SLT administration (eg, treatment of acute post- SLT IOP spi[INVESTIGATOR_2531]), in order to maintain masking 
of the ey e receiving study  treatme nt, the investigator will be instructed to dispense the 
required medication without disclosing which ey e is the Bimatoprost SR or SL T eye or the 
etiology  of the signs/s ymptoms that require the medication.
Allergan Confidential Protocol [ADDRESS_446786] SR or SL T using a 1:1 ratio, stratified by  [CONTACT_358195] (≤ 25 or > 25 mm Hg)  
.  If the primary  eye receives Bimatoprost SR, the contralateral eye will 
receive SL T.  If the primary  eye receives SL T, the contralateral eye will receive 
Bimatoprost SR.  If baseline IOP  is the same in both ey es, the right ey e will be the primary  
eye.
5.5 Method for Assignment to Treatment Gr oups/Randomization
Prior to initiation of any  study  procedures, each patient who provides informed consent will 
be assigned a patient number that will serve as the patient’ s identification numbe r on all 
study  documents.
For determination of stratification group assignment for the primary  eye for each patient, 
sites will be required to enter Baseline IOP (at Hour 0) data for both ey es into an automated 
interactive response s ystem.
At the time of r andomization (Day  1 SL T Administration Day ), an automated interactive 
response s ystem will be used to manage the randomization and treatment assignment for the 
Bimatoprost SR and SL T
.  A randomization number will be assigned to a patient according to 
the order of enrollment within each IOP  stratum ( Baseline primary  eye Hour 0 IOP  ≤ 25 or 
>
25mmHg)  
across the study .  That is, the interactive response sy stem will assign the next avai lable 
randomization number to the patient at the time when the investigator requests 
randomization.  
The interactive response sy stem will provide the site with the specific treatment assignment
for each randomized patient/ey e at the time of randomization (Day  1 SL T Administration 
Day).  Sites will contact [CONTACT_358196] e response sy stem at subsequent visits to obtain a study  
medication kit number for dispensing stud y medication (Bimatoprost SR and Sham) .  Study 
medication kitsfor Bimatoprost SR and Sham administration will be label ed with medication 
kit numbers.  Sites will receive interactive response system confirmation notif ications for 
each transaction .  All notifications are to be maintained with the study  source documents.
5.[ADDRESS_446787] SR on Day  4andat Week 16 (if retreatment criteria are met) ,
plus Sham SL T administration on Day  1only.  For those patients who do not meet 
retreatment criteria at W eek 16, the second Bimatoprost SR administration may be performed 
at the investiga tor’s discretion during an unscheduled visit after W eek 16 and prior to the 
Month 12 visit if the retreatment criteria are met .  The con tralateral ey e will receive one 360° 
SLT administration on Day  [ADDRESS_446788] SR administration on Day  4and
Week16 (or at the time of the second Bimatoprost SR administration for patients who 
receive it later than W eek 16 ).  Patients will receive the same dose strength throughout the 
study  (ie, patients in Stage 1 receive d15 µg and patients in Stage 2 will receive 10 µg).
For patients who still have an y visible Bimatoprost SR implants or have not received 
nonstudy  IOP-lowering medications 
by [CONTACT_358197], 
poststudy  evaluations including t he need for IOP -lowering medications should be conducted 
according to the treating phy sician’ s clinical opi[INVESTIGATOR_1649] .  Further patient follow - up will be 
determined b y the treat ing ph ysician’ s clinical opi[INVESTIGATOR_1649].
5.[ADDRESS_446789] be s tored as 
described in the Investigator ’s Brochure .  Sites must report an y temperatur e excursions as 
described in the Procedure Manual or contact [CONTACT_358198].
For further details on storage, including requirements for 
study-provided eye drops, please 
refer to the Procedure Manual and/or contact [CONTACT_78562].
5.8 Preparation of S tudy Medications/T reatments 
Bimatoprost SR is loaded into the single use applicator during manufacturing and is provided 
within the applicator as a ster ile, finished product.  Study site personnel should notify 
Allergan or its designee immediately  to advise of any  situation in which the study  medication 
is defective.
Allergan Confidential Protocol [ADDRESS_446790] only be administered to patients w ho meet the eligibility  criteria in 
accordance with the conditions specified in this protocol .  Medication will be labeled with 
either a single panel label or booklet label .  Records of use of medication kit numbers for 
each patient will be maintained by  t
he site and recorded in the electronic case report form 
(eCRF) as appropriate.
5.9.[ADDRESS_446791] SR Administration
[IP_ADDRESS] Patient Preparation
Administration day  assessments (including vital signs and query for concomitant medications 
and adverse events) should be comple ted.  At least [ADDRESS_446792] spectrum 
topi[INVESTIGATOR_358165]  5 minutes beginning approximately  15minutes prior to the 
procedure .  With the patient in a supi[INVESTIGATOR_2547], the ey e and conjunctival fornices should be 
irrigated with 5% ophthalmic povidone -iodine solution and the lids and surrounding orbital 
area should be prepped and draped according to the standard protocol detailed in the 
Procedure M anual.
[IP_ADDRESS] Study Treatment Location
At the discretion of the investigator , Bimatoprost SR (or Sham) administration may  be 
performed at an Ambulatory  Surgical Center (ASC; free standing or hospi[INVESTIGATOR_78515]) or in the 
of
fice setting (eg, in a procedure room with an operating microscope) .  As a standard ASC 
technique an intravenous catheter may  be placed and intravenous sedatives may  be used at 
the discretion of the investigator and/or anesthesiologist .  The ASC may  have standard 
operating procedures (SOPs) that req uire an electrocardiogram and/or a chest radiograph 
performed prior to th e procedure .  A separate standard consent to have the procedure at an 
ASC may  be required per the SOPs at the facility .
Sterile technique should be practiced at all times.
[IP_ADDRESS] Administrat ion Technique
Intracameral administration of Bimatoprost SR must be perfo rmed by  [CONTACT_358199] .  
The principal investig[INVESTIGATOR_136]or [INVESTIGATOR_136] a site may  designate a subinvestiga t
or to perform the procedure, 
Allergan Confidential Protocol [ADDRESS_446793] .  The ey e 
is stabilized by  [CONTACT_358200] a sterile toothed forceps or counter pressure with 
a cotton tipped applicator as the needle is advanced throu gh the cornea .  The actuator button 
is depressed until an audible and/or palpable click is heard.  The Bimatoprost SR implant 
should be visible exiting the needle bevel into the aqueous humor .  The needle is then 
immediately  removed from the AC, and the wound is checked for aqueous leakage .  
Following removal of the lid speculum and sterile drape, additional drops of broad spectrum 
antibiotics should be applied.
The procedure for the second administration of Bimatoprost SR is the same.
The preparation an d procedure for all sham administrations is the same; however , the sham 
applicator will not have a needle and thus will not enter the AC (but should touch the ey e at 
the area of recommended insertion).
[IP_ADDRESS] Immediate Posttreatment Observation
Following Bimatopr ostSRadministration, the patient is allowed to sit upright and is kept for 
a minimum of 1 hour of observation .  The surgeon will examine each of the patient’ s eyes to 
ensure that the AC is formed prior to the patient being released.
The patient will be s upplied a bottle of topi[INVESTIGATOR_358166] 3 day s (including the day  of the administration) in both ey es and to 
follow up as per protocol.
Prior to leaving the site, patients should be instructed to co ntact the stud y site immediately if 
they experience any  adverse events after treatment .  If the patient reports having experienced 
adverse events, these must be recorded on the appropriate eCRF .
The same posttreatment observation and antibiotic requirement s appl y after the second 
administration of Bimatoprost SR or Sham.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
48 GDD -TA-T-004 v 2015.10Note :  Patients with sickle cell disease or trait (or other hemoglobinopathies) may undergo 
optional biomicroscopy  and IOP  examination in both ey es [ADDRESS_446794] ration (or Sham administration) .  This optional IOP examination is for postoperative 
purposes only , and as such does not require use of the masked, 2- person reading method.  
The IOP  should be taken only  once to avoid excessive postadministration (or Sham 
administration) manipulation of the ey e, and should be taken by  [CONTACT_093] (or other 
unmasked, qualified personnel) .  This postadministration (or Sham administration) 
examination may  be performed using a Goldmann applanation tonometer or a hand- held 
tonometer (see the Procedure Manual for details).
[IP_ADDRESS] Retreatment with Bimatoprost SR
For all patients who meet retreatment criteria at Week 16, C ycle [ADDRESS_446795] SR
administration may occur at the investigator ’s discretion during an unscheduled visit after 
Week 16 and prior to 
the Month 12 visit based on the investigator ’s clinical judgment 
regarding the patient’ s IOP  control and if theretreatment criteria are met .  Note :  beyond 
Week 16, Cy cle [ADDRESS_446796] received nonstudy  IOP-lowering treatment (prohibited during the stud y 
except for pre -and post -SLT administration, Section 4.5.1) in only  1eye will still attend 
administration visits regardless of whether the ey e receiving additional medication is the 
Bimatoprost SR ey e or the SL T eye.  If the ey e treated wit hadditional nonstudy  IOP lowering 
medication is the Bimatoprost SR ey e, the ey e will receive Sham Bimatoprost SR 
administrations at the administration visits .  If the eye treated with additional nonstudy  IOP 
lowering medication is the SL T eye, that ey e will continue to receive Sham Bimatoprost SR 
administrations
.  Patients who have been treated with nonstudy  IOP-lowering medication in 
both eyes will not attend the administration day  visits, n or will they  attend the Day  2, Day 4 
(phone call), and W eek 2 (phone call) visits following an administration .  Patients who have 
received nonstudy  IOP-lowering medication in one or both ey es will be followed for the 
duration of the study  through the Month 24/Exit visit .  
Retreatment of an eligible implanted eye is per mitted if the following criteria are met in that 
eye
:
IOP > 17 mm Hg
There is no evidence of any  of the following:
Allergan Confidential Protocol 192024 -093 Ame ndment 7
49 GDD -TA-T-004 v 2015.10oSignificant corneal findings related to presence of the implant (including c orneal 
edema, peripherally  adjacent to the implant location and/o rcentral) at an y visit
oEndothelial cell density  less than 1800 cells/mm2 by [CONTACT_239796] , 
confirmed at 2 consecutive visits on separate day s
oPersistent and progressive corneal endothelial cell density  decrease ≥15% from 
baseline confirmed at 2 con secutive visits on separate day s(scheduled or 
unscheduled)
oRemaining implant size or position from prior administration that, based on the 
investigator ’s evaluation, preclude s placement of another implant (eg, may  cause 
chronic contact [CONTACT_358201] h the corneal endothelium)
oClinically  significant intraocular inflammatory  findings (eg, P AS, uveitis, 
iridocy clitis, macular edema , etc) at an y visit .  Note :  mild AC cells/i ritis related 
to the administration proc
edure itself that resolves rapi[INVESTIGATOR_375]  (with or without 
NSAIDs or steroids) is not prohibitive
In the investigator ’s opi[INVESTIGATOR_1649], it is safe for the study  eye to receive an additional 
administration of Bimatoprost SR
Signs o
r symptoms will be documented in the eCR F.
5.9.2 SLT Administration
[IP_ADDRESS] Pre-SLT Patient Pre paration
Measure the IOP in both ey es and record the result .  Because this is a preoperative 
measurement and not used for ef ficacy  analy ses, this measurement does not need to be 
masked and onl y 1 measurement needs t o
be performed.  
Instill 1 drop of aprac lonidine or brimonidine (see Procedure Manual) into each ey e 
30minutes to 1 hour prior to SL T (or Sham SL T).  Topi[INVESTIGATOR_69360] (eg, proparacaine 
hydrochloride or equivalent) should be administered to each ey e approximately  every  
5minutes beginning approximately  15minutes prior to the procedure .  
[IP_ADDRESS] SLT and Sham SL T Procedure
SLT must be performed by  [CONTACT_358202] .  The investigator will perfo rm360 degrees of SL T using the 
standard ized method that is detailed in the Procedure Manual .  Sham SL T will then be 
performed on the contralateral eye using the same method, with the exception that the laser is 
not
switched to the active state.  
Allergan Confidential Protocol 192024 -093 Ame ndment 7
50 GDD -TA-T-004 v 2015.[IP_ADDRESS] Post-SLT
Administer 1 drop of apraclonidine or b rimonidine into each ey e and recheck the IOP  1hour 
after SL T and Sham SL T administration; because this is a postoperative measurement and not 
used for ef ficacy  anal yses, this measurement does not need to be masked andonly 
1 measurement needs to be perfor med.  If an IOP  spi[INVESTIGATOR_358167], the investigator should 
treat using his/her standard of practice.
The patient will be supplied a bottle of topi[INVESTIGATOR_358168] f or the n ext3 days (including the day  of the admi nistration) in both ey es and to 
follow up as per protocol.
Prior to leaving the site, patients should be instructed to contact [CONTACT_43038] y site immediately if 
they experience any  adverse events after treatment .  If the patient reports having experienced 
adve rse events, these should be recorded on the appropriate eCRF
.
6. Response Measures and Summary of Data C ollection Methods
Detailed information on equipment and methodology  to be used is provided in the Procedure 
Manual .
Study evaluations should be performed b y the same investigator/subinvestigator throughout 
the study  whenever possible .  If it is not possible to use the same individual to follow the 
patient, then an attempt should be made to have investigators overlap ( examine the patient 
together and discuss findings) for at least [ADDRESS_446797] 2 measurements differ by > [ADDRESS_446798] 2 meas urements differ b y ≤ [ADDRESS_446799] 
2measurements is > 1 mm Hg, the IOP for the given ey e will be the median of the 
3 readings.
All Hour 0 IOP  examinations should be scheduled at 08:00 AM± [ADDRESS_446800] approximately  the same Hour 0 time of day throughout the 
study .  At selected sites in consenting patients, additional I OP measur ements will be 
performed at Hour 2 (Hour 0 + 2 hours [± 30 minutes]) and Hour 8 (Hour 0 + 8 hours 
[±30 minutes]).  
6.2 Safety Measures
The following will be collected and recorded on the appropriate eCRF page(s) :  
Adverse Events:  All adverse events, from the moment the patient signs the informed 
consent form, will be monitored and recorded in the patient’ s source docume nts
.  All events 
will be reported to Allergan on an adverse event eCRF , including seriousness, severity , action 
taken, and relationship to stud y drug .  If adverse events occur , the first concern will be the 
safet y of the stud y patient.
Weight and Height :  Weight will be measured in pounds (lb) or kilograms (kg) using a 
scale .  Height will be measured in inches (in) or centimeters (cm) .  Height and weight will be 
measured at Screening as part of the demographic data; historical patient information and/or 
patient reports should not be used for either measurement.
Vital signs :  Systolic and diastolic blood pressure and pulse rate will be measured after 
patients have been at rest (seated) for at least 5 minutes
.  Bod y temperature will be measured 
orally  (or with an infrared forehead thermometer) and recorded as °F or °C.
Blood and Urine Sample Collection :  Blood and urine samples will be collected f or blood 
chemistry , hematology  panels
, and urinal ysisby a central laboratory  or designated regional 
facility .  
Pregnancy :  Females of childbearing potential will have pregnancy  tests performed.  
Pregnancy  test kits will be provided by  [CONTACT_358203] a designated 
regional laboratory  and will be administered according to the instructions prov ided with the 
tests.  
Allergan Confidential Protocol 192024 -093 Ame ndment 7
52 GDD -TA-T-004 v 2015.10Measures of Ocular Safety :
Best Corr ected V isual Acuity :  Visual acuit y tests will be performed at all scheduled visits 
except on any  of the Bimatoprost SR admini stration days or SL T Administration Day .  
Manifest refraction using Sne llen equivalent with a logMar chart (see Procedure Manual) 
will be performed at Screening ;Baseline ;Weeks 12, 24, and 52; and Months 18 and 24/E xit .  
At all other visits, the visual ac uity technician will use the last manifest refraction performed 
and det ermine the Snellen equivalent visual acuity  using the logMar chart .  If there is a 2- line 
or more reduction in visual acuit y from the last best -corrected visual acuity performed, a 
repeat manifest refraction in both ey es and best- corrected visual acuit y will be performed.
Macr oscopic Iris Color Assessment :  Iris color will be assessed visually at each designated 
visit using the appropriate assessm ent guide (see the Procedure Manual for f urther details) .  
Macr oscopic Conjunctival Hyper emia Assessment :  Macr oscopic conjunctival hy peremia 
will be assessed using the appropriate assessment g uide (see the Procedure Manual for 
further details).
Gonioscop y/Angle Assessment :  Gonioscopic examinat ion for eligibility  at Screening (onl y) 
will be independentl y performed by 2 ophthalmologists as described in the Protocol 
Procedure Manual .  The independent eligibility  assessors should not share their assessments 
with each other until the assessment is r ecorded.  The 2 ophthalmologists’  independent 
eligibility  assessments must confirm patient eligibility  for participation in the study .  
Subsequent gonioscopic examinations will be performed by [CONTACT_1704] .  Using 
gonioscop y, the investigator wil l evaluate the inferior iridocorneal angle and the Bimatop rost 
SRimplant.
Biomicr oscopy
:  Biomicroscopic examinations will be performed using a slit lamp.  The 
examinations will include evaluation of the condition of the ey elids, conjunctiva, cornea, AC
(with Van Herick anterior chamber depth assessment at Scree ning onl
y), iris/pupil, and lens 
(Lens assessment is performed using the modified AREDS procedure and is collected on 
dilated examination day s through a dilat edpupil , using the slit lamp biomicroscope.  Pleas e
see the Procedure Manual for details )
.  
Lens Assessment :  Biomicroscopic findings will be evaluated for the presence and severit y 
of nuclear , cortical, and posterior subcapsular lens opacities .  See the P rocedure Manual for 
further details.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
53 GDD -TA-T-004 v 2015.10Optic Disc Examination :  The cup/disc ratio and presence of optic disc pathology  will be 
determined using stereoscopic evaluation.
Dilated Ophthalmoscopy :  The stereoscopic fundus assessments should be conducted 
thro
ugha dilated pupil .  The examinations wi ll include evaluation of the macula, vitreous, 
and retina.
Specular  Micr oscopy:  Endothelial cell density  will be assessed using specular microscop y 
performed on the central cornea at all sites.  The determination o f central endothelial cell 
density  for st udy entry  as well as study  visit measures will be determin ed by  [CONTACT_358204] .  See the Procedure Manual for further details .  The same instrument should be used 
throughout the stud y for a given patient .  Quali fication will remain valid for 1 y ear aft er 
Screening in patients who are not enrolled at the time of Screening, if in the investigator ’s 
opi[INVESTIGATOR_358169] (eg, ocular 
surgery) during that time.
Pachymetry :  Corneal thickness using ult rasound (contact) pach ymetry will be performed on 
the cent ral cornea .  The same instrument should be used throughout the study  for a given 
patient .  Contact [CONTACT_358205] y.  See the 
Procedure Manual for further detail s.
Anterior  Segment -Optical Coher ence Tomography:  Anterior segment -optical coherence 
tomograph y measurements will be performed at all sites and a Reading Center will be used to 
examine angle size for investigationa l purposes .  See the Anterior Segment Opt ical 
Coherence T omograph y Image Acquisition manuals from the Reading Center for further 
details on the use of optical coherence tomography .  In the event that the anterior 
segment -optical coherence tomograph y type a s specified in the manuals is not availab le, a 
suitable alternative may  be approved b y Aller gan and the designated reading center for use .  
The same instrument should be used throughout the study  for a given patient.
Visual Field :  Visual field examination s will be assessed using automated perime try (using 
either Humphrey  24-2 full threshold prog ram or 24 -2 Swedish Interactive Thresholding 
Algorithm (SITA) Standard, or Octopus G1 or 24 -2 and dy namic or normal strategy ).  The 
same test methodology  must be used throughout the entire stud y for a give n patient. Visual
field data may  also be subm itted to an Allergan designated vendor for additional evaluation.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
54 GDD -TA-T-004 v 2015.106.3 Other Measures
 
 
 
 
 
 
 
 
 
 
 
  
6.3.1 Medical History , Physical Examination, and Vital Signs 
[IP_ADDRESS] Medical History 
A standard medi cal history  (including all relevant conditions that the patient has had in the 
past or currently  has) will be captured in the patient sour ce documents .  All sur gical 
procedures should have an associated medical history  entry .  Current medications as well a s 
those stopped within [ADDRESS_446801] 3 months prior to study entry will be recorde don the appropriate source 
document and/or eCRF page.
[IP_ADDRESS] Physical Examination
The patient will be ex amined by  [CONTACT_358206] s ystems :  general appearance; head, ey es, ears, nose, and throat; 
heart/ca rdiovascular; lungs; abdomen; neurologic; extremities; b ack; musculoskeletal; 

Allergan Confidential Protocol 192024 -093 Ame ndment 7
55 GDD -TA-T-004 v 2015.10lymphatic; and skin. T he patient’ s height and weight will be recorded at the Screening visit 
only.
[IP_ADDRESS] Vital Signs
The below vital signs will be measured at all patient visits and should be recorded prior to 
any invasive procedures.
Pulse rate (beats per minute [bpm]) :  the pati entshould be resting in a seated position 
for a minimum of 5 minutes prior to measurement.  Pulse rate is then counted over 
30seconds (and multiplied by  2 t
o obtain bpm).
Blood pressure (mm Hg) :  the patient should be resting in a seated position for a 
minimum of 5 minutes prior to measurement .  Systolic/diastolic blood pressure will 
be measured with a sph
ygmomanometer (manual sphygmomanometer or automated 
blood pressure measuring device).
Temperature (°C/°F) :  the patient should be seated and the body  temperature taken 
orally  (or with an infrar ed forehead thermometer).
6.3.2 Pregnancy T esting
Urine will be collected from females of childbearing potential for pregna ncy testing (urine 
pregnancy  test) .  The urine test for pregnancy  will be performed at the site ut
ilizing the 
dipstick method at all specif ied timepoints.  Serum testing may  be performed instead of urine 
testing if required b y the local institution.  
Further, in countries/institutions where required by [CONTACT_5737] i nstitution or health authority , an 
additio nalserum test may be done an y time betwe en B aseline and Bimatoprost SR (or Sham)
administration.  N egative results for all pregnancy  tests are required to be confirmed prior to 
the time of Bimatoprost SR (or Sham) administration.  
6.3.3 Laboratory Pr ocedures
Acentral laboratory or designated regiona l facility will anal yze blood and urine specimens 
for this study ; including any  repeat laboratory  tests .  Blood and ur ine samples will be 
obtained for the anal ysis of blood chemistry , hematology , and urinal ysis.
Refer to the Central Laboratory  Manual for f urther details regarding central laboratory  
collection and shipment procedures.
Allergan Confidential Protocol [ADDRESS_446802] results 
that repre sent adverse events should be reflected on an adve rse event eCRF page.
Evaluation and management o f abnormal laboratory  results should be c onducted according to 
local site practice.
[IP_ADDRESS] Hematology 
Hematology  will be measured and includes hematocrit, hemoglobi n, glycated hemoglobin, 
mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, me a
n 
corpuscular volume, platelets, red blo od cell (RBC) count, RBC morphology , total white 
blood cell (WBC) count and dif ferential (neutrophils, bands, ly mphoc ytes, monocy tes, 
basophils, and eosinophils) .  
[IP_ADDRESS] Serum Chemistry 
Serum chemistry  will include albu min, alkaline phosphatase, alanine transaminase, aspartate 
transaminase, bicarbonate, calcium, c hloride, creatinine, creatine kinase, direct bilirubin, 
glucos e, indirect bilirubin, magnesium, phosphorous, potassium, sodium, total bilirubin, total 
cholester ol,total protein, urea nitrogen, and uric acid.
[IP_ADDRESS] Urinalysis 
Urine will be anal yzed for clarity ,color , bilirubin, blood, glucose, ketones, leukocy te 
esterase ,nitrite, pH, protein, specific gravity , urobilinogen, and microscopic sediment 
(WBCs, RBCs, cast s
, bacteria, cry stals, and epi[INVESTIGATOR_351285]).
6.4 Other S tudy Supplies
The following will be provide d by [CONTACT_358207]:
All supplies needed for central laboratory  blood and urine sampling (urinaly sis, blood 
chemistry , and hematology ), urine 
pregnancy  test kits, and ocular fluid col lection kits
Shippi[INVESTIGATOR_160337]  
  

Allergan Confidential Protocol 192024 -093 Ame ndment 7
57 GDD -TA-T-004 v 2015.10As needed :  anterior segment -optical coherence tomography , anterior segme nt-optical 
coherence tomograph ysoftware and/or module , Specular Microscope, contact 
(ultrasound
) pach ymetry equipment
  
Ancillary administration procedure supplies and postoperative to pi[INVESTIGATOR_358170] t able to receive supplies from Allergan due to country  regulations will need 
to provide their own supplies.
Allergan will not provide any nonstudy  IOP-lowering medications.
6.[ADDRESS_446803] 
party  vendor .  The data will be entered on the eCRFs in a timely  manner on an ongoing basis .  
The investigator is responsible for ensuring that data are properly  recorded on each patient’ s 
eCRFs and related docu ments.  An investigator who has signed the protocol signature [CONTACT_358235] c ase report forms (as indicated in the eC RFs) to ensure that the 
observations and findings are recorded on the eCRFs correctl y and completely .  A certified 
electronic copy  of the eCRF including data corrections will be provided to the site for 
archiving at the end of the study .
Acentral laborato ry or designated regional facility  will be used for ana lysis of blood 
chemistry  and hematology , urinal ysis, and ocula rfluid sample analy sis (if ocular fluid is 
obtained) .  Laboratory  data will be transferred to Allergan on a periodic basis throughout the 
study .
7. Statistical Pr ocedur es
The study  is being conduc ted in [ADDRESS_446804] SR 10 µg 
and SLT.  
Three database locks will be performed :  1) when all patients treated with Bimatoprost SR10
µgcomplete the Week [ADDRESS_446805] prematurely  discontinued befor ethe Week 24 
visit, 
2)when all patients treated with Bimatoprost SR 10µghave completed the Month 12 visit or 

Allergan Confidential Protocol 192024 -093 Ame ndment 7
58 GDD -TA-T-004 v 2015.10prematurel y discontinued before the Month 12 visit, and 3) when all patients trea ted with 
Bimatoprost SR10µghave complete dthe Month [ADDRESS_446806] database 
lock a detailed a nalysis plan will be finalized .  To maintain the integrit y of the ongoing study , 
Allergan stud y personnel who are directl y involved in data handling and supporting the trial 
(such as the cl inical stud y team) w illremain masked to treatment assignment of individual 
patients during the stud y.  To avoid potential data unmasking between locks and to protect 
trial int egrity , study  statistical personnel who have been unmasked after each lock will no
longer b e involved directly in an y ongoing masked study conduct .  Another statistician, who 
is still masked to study  treatment, will assume these responsibilities until the next lock .  
Unmasked data handling and appropriate data and results a ccess will b
e specified prior to 
each lock.
7.1 Analysis Populations
The i ntent -to-treat (ITT) population is defined as all patients randomized to receive 
Bimatoprost SR [ADDRESS_446807] SR10 µg , or S LT.  
The per -protocol (PP) population isdefined as all patients in the Bimatoprost SR [ADDRESS_446808] ingthe data for primary  efficacy  analy sis
for all visits (Week 4, W eek 12, and W eek 24 ).  The P P population will be used for selected 
efficac y analyses.  A list of patients with d ataexcluded from t he P P population will be 
finaliz ed prior to database lock.
The Bimatoprost SR [ADDRESS_446809] SR 10 µg , and SL T safet y populations are defined 
as all patients who received an y stud ytreatment sand will be used for safet y anal yses.
7.2 Collection and Deriv ation of Primary and Secondary Efficacy 
Assessments
The primary  efficacy  measurement is IOP , which will be measured in each ey e using the 
Goldmann applanat ion tonometer .  Two con secutive measurements will be taken for each 
eye
.  If these 2 measurements dif ferby> [ADDRESS_446810] 2 measurements differ b y ≤ [ADDRESS_446811] measurement is 
required but onl y 2measuremen ts are obt ained, then the IOP  value for a given ey e is the 
average of t he 2 me asurements . If 3 measurements are required (ie, the first 2 measurements 
differ by > 1 mm Hg) and obtained, then the IOP  value for the given ey e is the median of th
e
3 measureme nts.  If, for any  reason, onl y a single measurement is obtained, then t his 
measurement w ill be us ed as the IOP  value.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
59 GDD -TA-T-004 v 2015.10To avoid confounding of ef ficacy  data, IOP  measurements obtained after initiating the use of 
nonstudy  IOP-lowering medication in an ey e will be included in the study  database but will 
be excluded from ef ficacy analyses.
7.2.1 Primar y E
fficacy Variable 
The primary  efficacy  variable is IOP  change from baseline (follow up value minus baseline 
value) and the primary  time period is 24 wee ks(measureme nts for th eprimary  anal ysis are 
designated for the following timepoints :  Weeks 4, 12, an d 24). 
7.2.2 Secondary Efficacy Variables
Secondary  efficacy  variables include :  
Time to initial use of nonstudy  IOP-lowering treatment (as determined b y the
investigato r)
Percent age of Bimatoprost SR and SL T eyes achieving ≥ 20% reduction in IOP  from 
baseline
IOP changes from baseline at Weeks 8, 15, and [ADDRESS_446812] SR 10 µg -
treated ey es andSLT-treated e yesat each visit of Weeks4, 12, and 24 are:
Null hy pothesis :  the dif ference in mean IOP change from baseline betwe enthe 
Bimatoprost SR 10µgeye and SL T eye (Bimatoprost SR 10 µg minus SL T) is 
>
1.5mmHg.
Alternative h ypothesis :  the dif ference in me an IOP change from baseline between the 
Bimatoprost SR 10 µg eye and SL T eye (Bimatoprost SR 10 µg minus SL T) is 
≤ 1.[ADDRESS_446813] model for repeated measures 
(MMRM) .  The model will include I OP change fr om baseline as the response var iable and 
treatment, visit, ey e, baseline I OP, treatment -by- visit, visit -by-baseline , and visit - by-eyes 
interactions as covariates .  Unstructured correlation for study  visits and ey es will be used for
repeated measures on the same patient.  
The mean difference between the Bimato prost SR 10 µg eyes and SL T eyes (Bima toprost SR
10 µg minus SL T) and the corresponding 95% confidence interval (CI) will be constructed at 
each visit from MMRM anal ysis. Thenoninferior ity com parison for Bimatoprost SR 10µg
versus SL T at Weeks 4, 12, an
d 24 is the primary  analy sis.  If the upper limit of the 95% CI is 
≤ 1.[ADDRESS_446814] SR10 µg i s considered clinicall y noninferior to SL T 
if the upper limit of the 95% CI is ≤ 1.[ADDRESS_446815] as the MMRM model 
used for theprimary  analy sis.
Finally , handling of missing data will be supp lemented by  [CONTACT_358208][INVESTIGATOR_11300] (adding di f
ferent penalties tothe imputed values) approach.
7.3.[ADDRESS_446816] SR 10 µg
versus SL T is considered achieved if the up per limit of the 95% CI  is < 0 mm Hg at Weeks 4, 
12, and 24.
Time to Initial Use of Nonstudy IOP -lowering Treatment ( AsDetermined by [CONTACT_3786])
Time to initial use of nonstudy  IOP-lowering treatment from the date of the first study  
treatment will be estimated separatel yforBimatoprost SR [ADDRESS_446817] SR a nd SL T Eyes Achieving ≥ 20% Reduction in IOP
Num ber and percent of Bim atoprost SR [ADDRESS_446818] achieved a ≥ 20% 
reduction in IOP  by [CONTACT_358209] e will be summarized
.
IOP Change fr om Baseline at Weeks 8, 15, and [ADDRESS_446819] SR 10 µg and SL T eyeswill be t abulat ed for IO P change 
from baseline at W eeks 8, 15 and 20;

Allergan Confidential Protocol [ADDRESS_446820] SR 10 µg safety populations.  The Medical Dictionary  for Regulatory  Activities 
(MedDRA) nomenclature will be used to code adverse events and medic alhisto ry.  The 
numbe r and percent of patients reporting treatment emergent adverse events will be tabulated 
based on the primary  SOC and preferred terms .  Summary  tables will be generated for all 
adverse events regardless of causalit y as well as treatmen t
-relate dadverse even ts for the 
entire study  and by  [CONTACT_358210].  Other safety variables include vital signs (blood 
pressure, pulse rate, and temperature) and pregnancy  test results
.  Ocular safety  will be 
evaluated through assessment of visual acuity a nd vis ual field, eva luation of macroscopic 
bulbar conjunctival h yperemia and iris color , assessment of endothelial ce ll density  and 
corneal thickness, IOP  measurement, and biomicroscopic and ophthalmoscopic examinations 
(including gonioscop y with Bimatopro st SR implant assess ment, optic disc examination, and 
dilated fundus examination).
Ocular adverse events and safet y variables attributable to each ey e will be summarized by  
[CONTACT_358211] T eye, and nonocular safety  variables will be summarized by  [CONTACT_4676].

Allergan Confidential Protocol [ADDRESS_446821] SR 10µgwill provide approximate ly 98% power in showing 
noninferiority  in 3 out of 3 timepoints with a noninferiorit y margin of 1 .5 mm Hg, and 90% 
power in showi ng noninfe riority in 2 out of 3timepoints w ith a noninferiority  marg in of 1. 0
mm Hg, assum ing that both the betwee n-eyes and t he within -patient correlation coefficients 
are0.5.
Assuming a premature discontinuation rate of 10%, approximately [ADDRESS_446822] up to 28 visits and 5 phone calls .  The 
schedule 
includes the following :  
Screening (up to 28 day s); Washout period of up to 56days for both ey es; an d 
Baseline visit ( up to 3 day s)
SLT treatment (Da y 1)and pho necall(Day  2) 
Bimat oprost SR Cycle 1 adminis
tration ( Day 4); Cy cle1 Day  2 safet y visit; C ycle 1 
Day 4and W eek 2 ph one calls; and follow -up study  visits at Weeks 4, 8, 12, and 15
Allergan Confidential Protocol 192024 -093 Ame ndment 7
64 GDD -TA-T-004 v 2015.10Bimatoprost SR Cycle 2 administration (to occur at Week 16 for all patientswho 
meet retreatmen t criteria) ; Cycle 2 Day  2 safety visit; and Cycle2 Da y4 and Week 2 
phone calls
oPatients who do not receive Cy cle 2 administration at Week 16 will not attend 
the Cy cle 2 Administration Day  visit on Week 16, or the Day  2 Safe tyor Day 
4 and Week 2 phone c alls associated with admi nistration at W eek 16 .For 
these patients, Cy cle 2 may  beperformed at 
the investigator ’s discretion 
during an unscheduled visit after W eek 16 and prior to the Month 12 visit if 
the retreatment cr iteriaare met; in this case, inad equate control of IOP  should 
be confirmed at an other sc heduled or unsch eduled visit prior to init iation of 
Cycle 2 .  All Cy cle 2 visits will apply  at the time of the Cy cle 2 
administration
.
Follow -up visits at Weeks 20, 24, 28, 31, 36, 40, 44, 47, and 52 ; and Months 13, 14, 
15, 16, 18, 20, 22, and 24/E xit
Regardless of the t iming of Cy cle [ADDRESS_446823] udy visit .  However , if the Cy cle 2 Day 4or W eek 2 
Phone Calls overlap with a regularly scheduled visit, perform the regularl y 
scheduled visit .
Patients who receive the secon d administration of Bimatoprost SR at Week 16 
and patients who neve r receive a se cond adm inistration may ,at the 
investiga tor’s discretion, skip the visits at Months 13, 15 and 22 if the patient 
has received nonstud y IOP lowering medication in both ey es; has ≤ 25% of
each implant remaining in the ey e; and in the i nvestiga t
or’s clinical judgmen t, 
has no safet y or other concern that would require the patient to attend these 
visits .  Please note :  as described in Section 4.5.2 , each ey e should be 
evaluated on an individual basis when deter mining t he need for ad ditional
nonstudy  IOP-lowering treatments ; initiation of treatment in one ey e should 
not automatically  lead to initiation of treatment in the contralateral ey e.
IOP evaluati ons will occur at Hour 0 (08:00 AM ± 1 hour) in all patients.  Select ed patients at
selecte dsites 
will have additional I OP measurements performed at Hour 2 (Hour 0 + 2 hours 
[±30 minutes]) and Hour 8 (Hour 0 + 8 hours [± 30 minutes]).
Allergan Confidential Protocol 192024 -093 Ame ndment 7
65 GDD -TA-T-004 v 2015.10The study  visits sh ould adh ere as closel y as possible to the schedule shown in Table 2,
Table 3, Table 4, Table 5, and Table 6.
8.1 Patient Entry Procedures 
8.1.1 Overview of Entry Procedures
Prospective p atients as defined b y
the criteriain Section 4.3andSection 4.4
(inclusion/e xclusion criteria) will be considered for entry  into this study .
8.1.[ADDRESS_446824] also give authorization (US only ), data protection consent ( EU onl y), and other w ritten 
documentation in accorda nce with the relevant countr y and lo calprivacy  requirement s 
(where applicable) prior to an y stud y
-related pr ocedures or change in treatment .  
Each patient who provides informed consent will be assigned a patient number tha t willbe 
usedon patient docum entation throughout the study .  
8.[ADDRESS_446825] provide informed consen t prior to beginning an y drug washou t for the 
purposes of inclusion in this study .  Patients currently  being trea ted with IOP -lowerin g
medication(s)in either ey e will begin washout of these me dication (s)following c ompleti on 
of the screening procedures an d Reading Center c onfirmat ion of endothelial cell density  by 
[CONTACT_239796] .  
The screening and washout peri ods may  not be concu rrent.  The
w
ashout period will be up to 56days depending o n the minimum washout period s chedule 
below .
If patients cannot discontinue their prescri bed therap y for up to 
8weeks to meet the washout 
period for stud y entr y, the investiga tor may  switch the p atient’s medication to one that
requires a shorter washout i nterval dur ing the was hout of t he original medication ( Table7) .  
Nonetheless, the investigator should adhere to the minimum washout p eriod for all 
IOP-loweringmedi cations as indicated in Table7.
If, a
fter initial washout, the IOP does not meet entry  criteria and the investigator believes this 
is due to inadequate washout, if time remains in th e washou t period he/ s
hemay perform
additional wash out, as long as the total washout per i oddoes not e xceed 56days.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
66 GDD -TA-T-004 v 2015.10Table7 Minimum W ashout Peri od by [CONTACT_358212] (eg, PI[INVESTIGATOR_358171] N®, Carbachol, Pi[INVESTIGATOR_78518]®) 4days
Carbonic Anhydrase In hibitors (topi[INVESTIGATOR_8165] s ystemic) (eg, Diamox®, Trusopt®, 
Azopt®)4 days
Sympathomimetics ( eg, PROPI[INVESTIGATOR_44466]®, Epi[INVESTIGATOR_78520]®) 14 days
Alpha- agonists (eg, ALPHAGAN P, Iopi[INVESTIGATOR_5325]®) 14 days
Beta-adrenergic blocki ng agents (eg,Timoptic®, BETAG AN®, Betoptic®, Betoptic-
S®, Opti -Pranol ol®, Ocupress®, Tim optic XE®)28 days
Rho-kinase in hibitors (eg, Rhop ressa®, Glanatec®) [ADDRESS_446826] s thatincludethese medication s(eg, LUMIGAN, Xalatan, Trav atan, 
Rescula®, GANFOR T®)28 days
Com bination therapy (for exa mple, COMBIGAN®[28 days], Cosopt®[28 days], 
GANFORT®[28 days], Simbrinza®[14 days], Aza rga®[28 days], etc)longest minimum 
durat ion of any
component based 
on m edication class
For patient s underg oing a washout ,interi msafet y evaluation(s) of IOP at some time during 
the washo ut period may  be performed at the discretion of the investigator .
Note :  Medications sh ould only  be discont inued (was hedout) if the invest igator feels that it 
is safe and app
ropriate, and if the pa tient is willing to discontinue the medication for the 
duration of the study .  If the medication cannot be discontinued the n the patient will not be 
eligible for stu dy entry.
8.3 Procedures for Final S tudy Entry
The results from the scre ening ocular a nd phy sical examinations, and laboratory  tests 
(hematology /blood ch emistry /urinal ysis) must be evaluated and determined to be acceptable 
to the investigat or prior to the pati e
nt’s entry int o the study .  Ifrepeat laboratory  tests are 
done, th e
results must be revi ewed prior to study  treatment ini tiation on Day 1. Reading
Center qualification of endothelial cell density  must be confirm ed prior to beginning 
Washout .  After conf irmation of eligibility  on Day  1, the interactive response s ystem i s
contact[CONTACT_358213] .  However , this contact [CONTACT_46140] r randomization ma y take p lace at the 
end of the baseline day  visit if needed.  See Section 5.5for themethod for assi gnment to 
treatment groups/ra ndomizat ion.  
A patie nt is considered to have enrolled in the study  at the time of the f irst study  treatment 
administration (SL T or Sham S LT).
Allergan Confidential Protocol [ADDRESS_446827] of procedur e s for each scheduled visit. Additio nal
informatio non the examination procedures, equipmen
t, and techniques for the measures 
listed in this section is presented in the Procedure Manual.
Ocular examination procedures should be perform e d in the order liste dat each visit .  
Flexibility in proc e
dure order is allowed ,as indicated in the tables ( Table 2, Table 3, Table 4, 
Table 5, and Table 6).  Noncontact [CONTACT_358214] a t any time prior to 
gonioscopy (including before or after Hour 0 IOP) . Intraoc ular pressure should be measured 
at approximately  the same time of day  at each visit .  Hour 0 is define d as 8:00 AM± [ADDRESS_446828] be com pleted prior to p erforming an y 
examination pr ocedures that require pupil di lation.
Examiners performing IOP measurements should be masked to the patient’ s treatment group .  
Effort should be made to keep IOP  examiners mask ed to the patient’ s other evaluati on 
results.
8.4.[ADDRESS_446829] been obtained (as described i n 
Section 8.1.2 ), the procedures listed below are carried out .  Intraocular pressure 
measurements must be performed in 1 day; howeve r, other procedures (eg, postdilation a nd 
imag ing procedures) may be performed on a different day  as long as the screening 
procedures are completed within a 28- day period.  Perform pupil dilat ion/diagnostic 
proce dures after the completion of t he final IOP  measurement of t he day or on a dif fere nt 
day.
Collection of demographic data
Coll
ection of medical and ophthalmic history
Collection of adverse events
Collection of concomitant medications and procedures
Physical examination
V
ital signs (at re st ≥ 5 minute s)
Collection of blood a nd urine sampl e s
Allergan Confidential Protocol 192024 -093 Ame ndment 7
68 GDD -TA-T-004 v 2015.10The f ollowing procedures should be per formed in both ey es in the order below (procedures in 
bold should be done in the order shown) :
Pre
-Hour  0 examination (perform before Hour 0 IOP) :
oMacroscopic conjun ctival hy peremia assessment 
Manifest r efraction (Manifest refraction will be used to provide a correction for 
best-corrected visual acuity  testing .  At all study  visits, if there is a [ADDRESS_446830]- corrected visua l acuit y will be 
performed.)
Best- corrected visual acuity
Intraocular  pressure measur ement at Hour  0
Non-contact [CONTACT_78591] :  The fo llowing may  beperformed in an yorder , at an y 
time before g onioscop y (including p rior to H our 0 IOP) :
oVisual field (Two vi sual field tests are required prior to the administration 
procedure .  The first can be performed up to [ADDRESS_446831] be used for fields that are 
historical as well as fields performed throughout the study .)
oSpecular microscop y
oAnterior segment -optical coherence tomography  
o   
  Assessment 
will be repeated at W eek52and Month 24/ Exit and may  be performed at any  
interim study visit at the discretion of the investigator .)
oBiomicroscop y 
Gonios copy/angle as sessment (The examination at Screening will be independently  
performed b y 2 ophthalmologists for eligibility purposes .  Examination will also 
include,  
Pachy metry (may  be performe dat an y time after gonioscopy)
Pupil dilation (Post -dilation exam ination s below may be performed in an y order)
oDilated ophthalmoscopy
oOptic disc examination
Eligibili ty is then det ermined and the interactive response s ystem i s contac ted.

Allergan Confidential Protocol [ADDRESS_446832] been completed and the Reading 
Center has confirmed central endothelial cell density  (see Section 8.2for a descri ption of 
washout) .  
8.4.2 Baselin e Visit
TheBaseline v isit occ urs after the washout period has been completed .  Baseline visit 
procedures, excluding IOP  measurements (which must be pe rformed in 1 day), can be 
performed over a 3 -
day period; all must be complete d by [CONTACT_358215].  Perfo rm pupil dilation/diagnostic procedures a fter the completion of the final IOP  
measurement or 
on a dif ferent day.
Collection of me dical and ophthalmic history  (confirmation )
Collection of ad verse events
Collection of concomitant medica tions and procedures
Completio nof Visual Field Questionnaire -25 (VFQ -25)
Vital signs (at rest ≥ 5 minutes)
Pregnancy  test for females of childbearing potential (as defined in Section 4.5.3)
The following procedures should be performed in both ey es (procedures in bold should be 
done in the order 
shown) :
Pre-Hour  0 examination (perform before Hour 0 IOP) :
oMacroscopic conjunctival hy peremia assessment ( The examination ma y also 
include,  
Manifest r efraction (Manifes t refraction will be used to provide a correction for 
best-corrected visual acuity  testing .  At all study  visits, if there is a 2- line or mo re 
reduction in visual acuit y from the last best -corrected visual acuity performed, a 
repeat manifest refraction in both ey es and best- corrected visual acuit y will be 
performed.)
Best- corrected visual acuity
Intraocular  pressure measur emen t at Hour 0 
Non-contact [CONTACT_78591] :  The following may be performed in an y order , at an y 
time before Hour 8IOP (including prior to Hour 0 IOP) :
oMacroscopic iris color assessment
oVisual field (If dilation is required to perform this test, then the visual field 
test should be performed after the last IOP  measurement of the day .)

Allergan Confidential Protocol 192024 -093 Ame ndment 7
70 GDD -TA-T-004 v 2015.10oBiomicroscop y (The examination ma y also in clude,  
)
Intraocular  pressure measur ements at Hour s 2 and 8 (at sel ected sites in 
consenting patients)
Pupil dilation (post -dilation exam ination s below may be performed in an y order)
oDilated ophthalmoscopy
oOptic disc examination
Determine eligibility  and enter Hour 0 IOP into the interactive response s ystem.  
8.4.3 Treatment P eriod
[IP_ADDRESS] Day 1 SL T Administration
The following procedures are performed on the day of SL T or Sh
am SL T administration:
Collection of adverse events
Collection of concomitant medications and procedures
Vital signs (at rest ≥ 5 mi nutes)
Confirm eligibility
Cont act interactive response sy stem for randomization (this contact [CONTACT_358216] 
1day prior to the admi nistration day , if needed)  
Preoperative IOPmeasurement (measurement does not need to be masked and only  
1measurement needs to be perf ormed)
Administer assigned study treatment (360 or Sham SL T; see details in Section 5.9.2 )
Postoperative biomicroscopy
Postoperative IOPmeasurement (measurement does not need to be masked and onl y 
1 measurement needs to be per form ed)
All patients must remain at the surgical facility for at least 1 hour for bilateral eye 
exami nation after 360 or Sham SL T administration .  
Each patient will be supplied a bottle of topi[INVESTIGATOR_358172] D ey edrops and instru ctions to use 
them 4 times dail y for the next 3 days (including the day of the administration) in both eyes 
and to follow up as per p rotocol.

Allergan Confidential Protocol 192024 -093 Ame ndment 7
71 GDD -TA-T-004 v 2015.[IP_ADDRESS] Day 2 (Phone Call)
On the day  after study  treatment administration, the patient will be contact[CONTACT_358217]:
Collecti on of adverse events
Collection of concomitant medications and procedures
If the patient reports s ymptoms or findings of concern in the Day  2 phone call (including but 
not limited to photophobia, blurred vision, ey e pain, vit reous floaters ), the invest igator must 
bring the patient in for ophthalmic examination .
[IP_ADDRESS] Day 4 (Bimatopr ost SR Cycle 1 Administration)
The following procedures are performed on the day of Bimatoprost SR administration:
Collection of adverse events
Collectio n of concomita nt medication s and procedures
Vital signs (at rest ≥ 5 minutes)
Contact [CONTACT_358218] (this contact [CONTACT_358216] 
1day prior to the administration day , if needed)    
Administer assigned study treatment (Bimatoprost SR or Sham Bimatop rostSR; see 
details in Section 5.9)
Contact [CONTACT_358219] [ADDRESS_446833] S R administration or sham administration procedure .  For patients with 
sickle cell disease or trait (or other hemoglobinopathies), the investigator may  perform 
optional 
biomicr oscopy  and measure IOP  in both ey es 4 hours after t he administration
procedure as desired.  This I OP examination is for postoperative purposes only , and as such 
does not require a masked, 2- person reading method.  The IOP  should be taken only  once to 
avoid excessive postadministration (or sham administration) manipulation of the ey e, and 
should be taken b y the investigator (or other unmasked , qualified personnel) .  This 
postadministration (or sham administration) ex amination may  be performed using a 
Goldmann applanation tonometer or a hand- held tonometer .  See full procedur e instruction s 
in the Procedure Manual.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
72 GDD -TA-T-004 v 2015.10Each patient will be supplied a bottle of topi[INVESTIGATOR_78530] 3 day s (including the day  of the administration) in both ey es and to 
follow up as per protocol.
[IP_ADDRESS] Cycle 1:  Day 2 (Cycle 1 Safety Visit)
The following procedures are performed on Cy cle 1 Day  2:
Collection of adverse events
Collection of concomi tant medications and procedures
Vital signs (at rest ≥ 5 minutes)
The following procedures should be performed in both ey es (procedures in bold should be 
done in the order shown) :
Pre-Hour  0 examinations (may  perform in an y order before Hour 0 IOP) :  
oMacroscopic conjunctival hy peremia a ssessment ( The examination may  also 
include,  
)
oBest-corrected visual acuity
Intraocular  pressure measur ement at Hour  0
Non-
contact [CONTACT_5148] :  The following may be performed at an y time after the 
pre-Hour 0 examinations (including prior to Hour 0 IOP) :  
oBiomicroscop y (The examination may  also include,  
 
.)
[IP_ADDRESS] Cycle 1:  Day 4 and Week 2 (Cycle 1 Phone Calls)
On Cy cle [ADDRESS_446834] 
the following:
Collection of adverse events
Collection of concomitant medications and procedures
If the patient reports s ymptoms or findings of concern in the Day  4 or W eek 2 phone call 
(includ
ing but not limited to photophobia, blurred vision, ey e pain, vitreous floaters), the 
investigator must b ring the patient in for ophthalmic examination.

Allergan Confidential Protocol 192024 -093 Ame ndment 7
73 GDD -TA-T-004 v 2015.[IP_ADDRESS] Cycle 1:  Weeks 4, 8, 12, and 15
The following procedures are performed at W eeks 4 ( ±4 day s), 8 (± 4 da ys), 12 ( ±4 day s), 
and 15 (±4days):
Collection of adverse events
Collection of concomitant medications a nd procedures
Vital signs (at rest ≥ 5 minutes)
The following procedures should be performed in both ey es (procedures in bold should be 
done in the order shown) :
Pre-Hour  0 examinations (may  be performed in any  order before Hour 0 IOP):
oMacroscopic conjunctival hy peremi a assessment ( The examination may  also 
include,  
.)
oBest-corrected visual acuity
Intraocular  pressure measur ement at Ho ur 0 
Non-contact [CONTACT_78591] :  The following may be performed in an y order ,at an y 
time before gonioscop y
(including prior to Hour 0 IOP):
oMacroscopic iris color assessment (W eeks 4 and 12 only )
oManifest refraction (W eek 12 only )
oSpecular microscop y (Weeks 4 and 12 onl y)
oBiomicroscop y (The examination may  also include,  
 
.)
Intraocular  pressure measur ement at Hours 2 and 8(at selected sit es in 
consenting patients; W eek 12 only )
Gonioscopy/angle assessment (The examination will also include,  
.  Perform 
gonioscop y at least 2 hours prior to H8 IOP measurement a t Week 12.)
Pachy metry  (may be done any  time after gonioscopy ;Weeks 4 and 12 onl y)
Pupil dilation (Week 12 only )(post dilation exam ination s below may  be performed 
in any  order)
oDilated ophthalmoscopy  (Week 12 only )
oOptic disc examinatio n (W eek 12 only )

Allergan Confidential Protocol 192024 -093 Ame ndment 7
74 GDD -TA-T-004 v 2015.[IP_ADDRESS] Bimatopr ost SR Cycle 2 Day 1 Administration
The following procedures are performed at W eek 16 (-2/+4 days)for all patients who meet 
retreatment criteria .  
Patients who do not receive Cy cle 2 administration at Week 16 will not attend the Cycle 2 
Administra tion Day  visit on Week 16, or the Day  2 Safety  or Day  4 and Week 2 phone calls 
associated with administration at Week 16 .  For those patients not meeting retreatment 
criteria at W eek 16, Cy cle 2 may  be performed at the investigator ’s discretion during an 
unscheduled visit after W eek 16 and prior to the 
Month 12 visit if the retreatment criteria are 
met; in this case, inadequate control of IOP  should be confirmed at another scheduled or 
unscheduled visit prior to initiation of Cy cle 2 .  For patients who begin Cycle2 after W eek 
16 and before Month 12, the Cy cle 2 visits 
(Administration Day , Day  2 Safety  Visit , and Day  
4 andWeek 2 Phone Calls) will apply  at the time thatCycle 2 occurs .  Regardless of the 
timing of Cycle 2, all regularly  scheduled visits should be completed .  Cycle 2 should be 
scheduled such that the Administration Day  and the Day  2 Safet y Visit do not occur on the 
day of a regularl y scheduled study  visit .  However , if the Cy cle 2 Day  4 or W eek 2 Phone 
Calls overlap with a re gularly  scheduled visit, perform the regularl y scheduled visit .
Collection of adverse events
Collection of concomitant medications and procedures
Vital signs (at rest ≥ 5 minutes)
Contact [CONTACT_358220] (this contact [CONTACT_358216] 
1day prior to the Cy cle 2 administration day , if needed)
Administer assigned study treatment
Contact [CONTACT_358221] n at least [ADDRESS_446835] SR administration or sham administration procedure .  For patients with 
sickle cell disease or trait (or other hemoglobinopathies), the investi gator may  perform 
optional 
biomicroscopy  and measure IOP  in both ey es 4 hours after the administration 
procedure as desired.  This I OP examination is for postoperative purposes only , and as such 
does not require a masked, 2- person reading method.  The IOP  should be taken only  once to 
avoid excessive postadministration (or sham admin istration) manipulation of the ey e, and 
should be taken b y the investigator (or other unmasked , qualified personnel) .  This 
postadministration (or sham administration) examinatio n may  be performed using a 
Goldmann applanation tonometer or a hand- held tonom eter.  See full procedure instructions 
in the Procedure Manual.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
75 GDD -TA-T-004 v 2015.[IP_ADDRESS] Cycle 2:  Day 2 (Cycle 2 Safety Visit)
The following procedures are performed on Cy cle 2 Day  2:
Collection of adve rse events
Collection of concomitant medications and procedures
Vital signs (a t rest ≥ 5 minutes)
The following procedures should be performed in both ey es (procedures in bold should be 
done in the order shown) :
Pre-Hour  0 examinations:
oMacroscopic conjunctival hy peremia assessment ( The examination may  also 
include,  
)
oBest-corrected visual acuity
Intraocular  pressure measur ement at Hour  0
Non-contact [CONTACT_5148] :  The following may be performed at any time after the 
pre-Hour 0 examinations (including prior to Hour 0 IOP ):
oBiomicroscop y (The examination may  also include,  
 
)
[IP_ADDRESS] Cycle 2:  Day 4 and Week 2 (Cycle 2 Phone Calls)
On Cy cle [ADDRESS_446836] 
the foll owing:
Collection of adverse events
Collection of concomitant medications and procedures
If the p atient reports s ymptoms or findings of concern in the Day  4 or W eek 2 phone call 
(including but not limited to photophobia, blurred vision, ey e pain, vitreous floaters), the 
investigator must bring the patient in for ophthalmic examination.
[IP_ADDRESS] Weeks 20, 24, 2 8, and 31
The following procedures are performed at W eeks 20 (± 4 day s), 24 ( ±4 day s), 28 (± 4 day s), 
and 31 ( ±4 day s):

Allergan Confidential Protocol 192024 -093 Ame ndment 7
76 GDD -TA-T-004 v 2015.10Collection of adverse events
Collection of concomitant medications and procedures
Vital signs (at rest ≥ 5 minutes)
The followi ng proce dures should be performed in both ey es (procedures in bold should be 
done in the order shown) :
Pre-Hour  0 examinations:
oMacroscopic conjunctival hy peremia assessment ( The examination may  also 
include,  
)
oBest-corrected visual acuity
Intraocular  pressure measur ement at Hour  0 
Non-contact [CONTACT_78591] :  The following may be perform edin an y order ,at an y 
time before gonioscop y(including prior to Hour 0 IOP ):
oMacroscopic iris color assessment (W eek 24 only )
oManifest refraction (W eek 24 only )
oVisual field ( If dilation is required to perform this test, then the visual field 
test should be performed after the l ast IOP  measurem ent of the day .) (W eek 24 
only)
oSpecular microscop y (Week 24 onl y)
oBiomicroscop y (The examination may  also include,  
 
)
Intraocular  pressure measur ement at Hour s
2and 8 (at selected sites in 
consenting patients; W eek 24 only )
Gonioscopy/angle assessment (The examination will also include,  
)
Pachy metry  (Week 24 only ) (may  be done any  time after gonioscopy )
Pupil dilation (may perform post -dilation ey e exams in any  order; Week 24 only )
oDilated ophthalmoscopy  (Week 24 only )
oOptic disc examination (W eek 24 only )

Allergan Confidential Protocol 192024 -093 Ame ndment 7
77 GDD -TA-T-004 v 2015.[IP_ADDRESS] Weeks 36, 40, 44, 47, and 52 ; and Months 13, 14, 15, 16, 18, 20, 
22, and 24 /Exit
The following procedures are performed at W eeks 36 (± 4 day s), 40 (± 4 day s), 44 (± 4 day s), 
47 (± 4 day s), and 52 (± 4days)and Months 13 (± 4days), 14 (± 4days), 15 (± 4days), 
16(± 4days), 18 (± 7 da ys) , 20 (± 7 day s)¸ 22 (± 7 day s)¸and 24/Exit (± 7 day s).
Patients who receive the second administration of Bimatoprost SR at Week 16 and patients 
who never receive a second administration may , at the investigator ’s discretion, skip the 
visits at Months 1 3, 15 and 22 if the patient has received nonstud y IOP lowering medication 
in both ey es; has ≤ 25% of each implant remaining in the ey e; and in the investigator ’s 
clinical judgment, has no safety or other concern that would require the pat ient to attend 
these visits.  Please note :  as described in Section 4.5.2 , each ey e should be evaluated on an 
individual basis when determining the need for additi onal nonstudy  IOP-lowering treatments; 
initiation of treatment in one ey e should n ot automatically  lead to initiation of treatment in 
the contralateral ey e.
Collection of adverse events
Collection of concomitant medications and procedures
Vital signs (at r est ≥ 5 minutes)
Pregnancy  test for females of childbearing potential (as defined in Section 4.5.3) 
(Month 24
/Exit only )
The following procedures should be performed in both ey es (procedures in bold should be 
done in the order shown) :
Pre
-Hour  0 examinations (may  perform in an y order before Hour 0 IOP) :
oMacroscopic conjunctival hy peremia assessment ( The examination will also
include,  
 
 may  be performed at interim visits for appearance of or 
increase /decrease in hy peremia .)
oBest-corrected visual acuity
Intraocular  pressure measur ement at Hour  0
Non-contact [CONTACT_78591] :  The following may  be perform edin an y order ,at an y 
time before gonioscop y(including prior to Hour 0 IOP ):
oMacroscopic iris color assessment ( Week 52 and Month
s 18 and 24/Exit only )
oManifest refraction ( Week 52 and Month
s 18 and 24/Exit only )

Allergan Confidential Protocol 192024 -093 Ame ndment 7
78 GDD -TA-T-004 v 2015.10oVisual field  ( If dilation is required to perform this test, then the visual field 
test should be performed after the last IOP  measurement of the day .) (W eek 52
and Mo
nths 18 and 24/Exit only )
oSpecular microscop y (Weeks 40 and 52 and Month
s 16, 20, and 24/Exit on ly)
o (at Week 52 and Month 24/Exit at 
selected sites in both ey es of all 
consenting patients who underwent 
assessment at Screening ; may  be done at interim visits at the discretion of the 
investigator .  Perform any  contact [CONTACT_358222].)
oBiomicroscop y (The examination will also include,  
 
 may be performed at 
interim visits for appearance of or increase /decrease in hy peremia .) 
Gonioscopy/angle assessment (The examination will also include,  
) 
Pachy metry  (Weeks 40 
and52and Months 16, 20, and 24/Exit only ) (may  be done 
any time after gonioscopy )
Pupil dilation 
(Weeks 40 and 52 and Months 16, 20, and 24/Exit only ) ( post dilation 
exams below may  be performed in any  order )
oDilated ophthalmoscopy  (Weeks 40 and 52 and M onths 16, 20, and 24/Exit 
only)
oOptic disc examination ( Weeks 40 and 52 and Month s 16, 20, and 24/Exit 
only)
Contact [CONTACT_358223] 24/Exit to report patient’ s exit status
8.[ADDRESS_446837] be able to adhere to the stud y visit schedule; appropriate inclusion, exc lusion, 
and treatment criteria; permitted and prohibited medication criteria; and testing parameters as 
descr ibed in the protocol .  At each study  visit, patients will be asked if they  have used their 
study -provided ey e drops as instructed and whether they  have used any  concomitant 
medications/therapi[INVESTIGATOR_358173] y concurrent procedures since the previous visit.
Patients should be scheduled for stud y visits as closely to the day specified in the visit 
schedule as possible.
8.9 Early Discontinuation (Early Exit) of Patients
Patients may  voluntaril y withdraw from the stud y at an y time.
Patients who have received nonstudy  IOP-lowering medication in one or both eyes, or who 
do not 
undergo Cycle 2 administration , will be followed for the duration of the study  through 
the Month 24/Exit visit .  If the implant has been removed, the patient may  discontinue the 
study  if based on investigator assessment the ey e is in stable condition, at which time they  
should complete the Month 24/Exit visit procedures.
Notification of early patient discontinuation from the study  and the reason for discontinuation 
will be made to Allergan and will be clearly  documented on the appropriate case report form.
When patients discontinue before Month 24/Exit, the site should complete all procedures for 
the Month 24/Exit visit at the patient’ s last visit.
Allergan Confidential Protocol [ADDRESS_446838] administration (or Sham), failure to undergo an Administration Day  visit does 
not indicate total withdrawal from the study .  Patients who have received nonstudy  
IOP
-lowering treatment in one or both ey es,or who do not undergo Cycle 2 administration,
will continue through the duration of the study.  
The investigator should consider withdrawing a patient from the study  early if any of the 
following criteria are met:
Patient develops (or has an exacerbation of) a medical condition that, in the opi[INVESTIGATOR_8574] , compromises the patient’ s ability  to participate in the study
Patient is unwilling or unable to continue to comply with stud y procedures
Patient is unwilling or unab le to continue in the study
If a patient develops (or has an exacerbation of) a medical condition that, in the opi[INVESTIGATOR_13046] , would put the patient at an unacceptable medical risk by  [CONTACT_358224], the patien t will be withdra wn from the study .
Whenever possible, the decision to withdraw a patient from the study  or study  treatment 
should be discussed with Allergan.
8.11 Study Termination
The study  may  be stopped at his/her study  site at any  time by  [CONTACT_358225].  Allergan 
may stop the study  (and/or the study  site) for an y reason with appropriate notification.  In the 
event that the study  is stopped, patients will be followed for [ADDRESS_446839] SR (or Sham) administration, after which t hey will return t o standard of care as 
per the investigator ’s discretion.  
9. Adverse Events 
Adverse events occurring during the stud y will be recorded on an adverse event case report 
form .  If adverse events occur , the first concern will be the safet y of t he study  particip ants.  
Allergan Confidential Protocol [ADDRESS_446840] a causal 
relationship with the tr eatment .  An adve rse event can therefore be an y unfavorable and 
unintended sign (including an abnormal laboratory finding), s ymptom, or disease temporally  
associated with the use of a medicinal (investigational) product, whether or not related to the 
medic inal (investigational) product .  This definition includes events related to the medical 
(investigational) product (Bimatoprost SR implant and applicator combination) or 
comparator medical device (SLT), and events related to the procedures involved, and als o 
includes an y ma lfunction or deterioration in the characteristics and/or performance of a 
device .  During the screening period, adverse events will be assessed regardless of the 
administration of a pharmaceutical product .  
Note :  Adverse events must be c ollected once informed consent has been obtained, regardless 
of whether or not the patient has been administered study
 treatment.
Progression of treatment indication including new or worsening of anticipated clinical signs 
or sy mpto ms, which are collected as clinical efficacy  variables and assessed as unequivocall y 
associated with the disease progression and /or lack of efficacy , should NOT  be reported as 
adverse events unless the disease progression is greater than anticipated in th e natural course 
of the disease.
IOP return to baseline following the cessation of the Bimatoprost SR treatment ef fect should 
not be considered an adverse event.
Adverse events will be assessed, documented, and recorded in the eCRF throughout the stud y 
(ie, after informed consent has been obtained) .  At each visit, the investigator will begin b y 
query ing for adverse events by  [CONTACT_229298] a general, nondirected question such as 
“How have you been feeling since the last visit?”  Directed questioning a nd examination will 
then be done as appropriate.  All reported adverse events will be documented on the 
appropriate case report form.  
9.1.2 Serious Adverse Event
A serious adverse event is any  adverse event occurring at any  dose that results in any  of the 
following outcomes :  death, a life -threatening adverse event, inpatient hospi[INVESTIGATOR_8448], a persistent or significant disability/incapacity , or a 
Allergan Confidential Protocol 192024 -093 Ame ndment 7
82 GDD -TA-T-004 v 2015.10congenital anomal y/birth defect .  Important medical events that may  not result in death, be 
life-threatening, or require hospi[INVESTIGATOR_227334] a serious adverse event when, 
based upon appropriate medical judgment, they  may  jeopardize the patient or subject and 
may require medical or surgical intervention to preven t one of the outcomes listed in this 
definition .  (See Section 9.3for procedures for reporting a serious adverse event.)
Allergan considers all can cer adverse events as serious adverse events .  In addition, Allergan 
considers an y abortion (spontaneous or nonspontaneous) as a serious adverse event.
Pre-planned surgeries or procedures for pre -existing, known medical conditions for which a 
patient requi res hospi[INVESTIGATOR_358174] a serious adverse event.
Any pre-planned surge ry or procedure should be clearl y documented in the site source 
documents by  [CONTACT_358226]’ s entry  into the 
study .  If it has not been documented at the time of the patient’ s entry  into the study , then it 
should be documented as a serious adverse event and reported to Allergan.
9.1.[ADDRESS_446841] be completed using the following defini tions as 
guidelines:
Mild Awareness of sign or s ymptom, but easily  tolerated.
Moderate Discomfort enough to cause interference with usual activity.
Severe Incapacitating with inability  to work or do usual activity .
Not applicable In some cases, an adver se event may  be an “all or nothing” finding 
which cannot be graded.
9.1.4 Relationship to S tudy Drug, Device, or Procedure
A determination will be made of the re lationship (if an y) between an adverse event and the 
study  drug, device, or procedure, as applicabl e.  A causal relationship is present if a 
determination is made that there is a reasonable possibility  that the adverse event may  have 
been caused b y the stu dy drug, device, or procedure.  
Allergan Confidential Protocol 192024 -093 Ame ndment 7
83 GDD -TA-T-004 v 2015.10If an adverse event is deemed related to stud y drug or device, the investigator will be asked 
to further delineate whether the adverse event was related to the administration procedure 
(versus the stud y drug or device).
Note :  A study  procedure occurring during the screening/baseline period can include a 
washout of medic ation or study  required diagnostic procedure.
9.[ADDRESS_446842] be recorded on the appropriate case report form.
All adverse events that are study  drug or device -related and unexpected (not listed as 
treatment -related in the current Investigator's Brochure) must be reported to the governing 
Institutional Review Board/I ndependent Ethics Committee (I RB/IEC) as requ ired by  [CONTACT_5040]/IEC, local regulations, and the governing health authorities .  Any adverse event that is 
marked “ongoing” at the exit visit must be followed- up as appropriate.
9.3 Procedures for Reporting a Serious Adverse Event
Any serious adverse event occur ring during the study  period (beginning with informed 
consent and continuing through the final study  visit ) and for at least [ADDRESS_446843] be reported to Allergan (or Agent of 
Allergan) as listed on th e Allergan Stud y Contacts Page and recorded on the serious adverse 
event form .  All patients with a serious adverse event must be followed up and the outc omes 
reported .  The investigator must supply  the sponsor and the IRB/IEC with any  additional 
requested information (eg, autops y reports and discharge summaries) .  
In the event of a serious adverse event, the investigator must:
1.Notify  Allergan immediately  by [CONTACT_358227] 
(contact [CONTACT_249620] 1 of the serious adverse event form); phone 
numbers and relevant Allergan personnel contacts are also on the front page of 
protocol and Study Contacts Page.
2.Obtain a nd maintain in his/her files all pertinent medical records, information, and 
medical judgments from colleagues who assisted in the treatment and follow- up of 
the patient.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
84 GDD -TA-T-004 v 2015.103.Provide Allergan with a complete, written description of the adverse event(s) on the 
serious adverse event form describing the event chronologically , including any  
treatment given (eg, me dications administered, procedures performed) for the adverse 
event(s) .  Summarize relevant clinical information about the event :  signs, sy mptoms, 
diagno sis, clinical course and relevant clinical laboratory  tests, etc
.  Include any  
additional or alternative explanation(s) for the causality  which includes a statement as 
to whether the event was or was not related to the use of the study  drug, device, or 
procedure.
4.Promptly  inform the governing I RB/IEC of the serious adverse event as required by  
[CONTACT_1201]/IEC, local regulations, and the governing health authorities.
9.[ADDRESS_446844] site staf f (eg,study  coordinator) are unmasked.  When 
necessary  for the safet y and proper treatment of the patient, t he investigator can unmask the 
patient and/or other site personnel .  
When possible, the sponsor (Allergan Medical Safety Ph ysician) should be notified p rior to 
unmasking the patient and/or other site personnel .  In instances where this is not possible, th e 
sponsor should be notified as soon as possible thereafter.  
The reason for unmasking the patient and/or other site personnel must be recorded in the 
patient’ s source documents.
10. Administrative Items
This protocol is to be conducted in accordance with th e applicable Good Clinical Practice 
(GCP) regulations and guidelines, eg, the International Conference on Harmonisation (I CH) 
Guideline on GCP , Allergan SOPs, and the applicable regulatory  requirements.
10.1 Protection of Human Patients
10.1.1 Compliance With Informed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations
Written informed consent is to be obtained from each patient prior to any  study -related 
activities or procedures in the study , and/or from the patient's legall y authorized 
representa tive.  If the patient is under the legal age of consent, the consent form must be 
Allergan Confidential Protocol [ADDRESS_446845] be obtained fro m Allergan personnel.
10.1.2 Compliance With IRB or IEC Regulations
This study  is to be conducted in accordanc e with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations
.  The investigator must obtain approval from a properl y 
constituted I RB/IEC prior to initiating the study  and re -approval or review at least annually .  
Allergan is to be notified immediately if the responsible I RB/IEC has been disqualified or if 
proceedings leading to disqualification have begun .  Copi[INVESTIGATOR_3951] I RB/IEC corresponde nce 
with the investigator should be provided to Allergan.
10.1.[ADDRESS_446846] been 
fulfilled.
10.1.5 Compliance With Electr onic Records; Electr onic Signatures 
Regula tions (US 21 CFR Part 1 1)
This study  is to be conducted in compliance with the regulations on electronic record s and 
electronic signature.
10.[ADDRESS_446847] not implement any  deviation from or changes of the protocol without 
approval b y Allergan and prior review and documented approval/favorable opi[INVESTIGATOR_358175] 192024 -093 Ame ndment 7
86 GDD -TA-T-004 v 2015.10IRB/IEC of a protocol ame ndment, except where necessary  to eliminate immediate hazards 
to study  patients, or when the changes involve only logistical or administrative as pects of the 
study  (eg, change in monitors, change of telephone numbers).
10.3 Patient Confidentiality
A report of t he results of this study  may  be published or sent to the appropriate health 
authorities in any  country  in which the study  drug may  ultimatel y be marketed, but the 
patient’ s name [CONTACT_160491] .  The patient's name [CONTACT_358236] , Allergan, or the governing health authorities or the 
FDA  if they  inspect the study  records .  Appropriate precaution s will be taken to maintain 
confidentiality  of medical records and personal information.
10.3.1 Patient Privacy
Written authorization (US sites only ), data protection consent (European sites only ), and 
other documentation in accordance with the relevant country  and local privacy  requirements 
(where applicable) is to be obtained from each patient prior to enrollment into t he study , 
and/or from the patient's legally  authorized representative in accordance with the applicable 
privacy  requirements (eg, the Health Insu rance Portability  and Accountability  Act Standards 
for Privacy  of Individually Identifiable Health Information (“HIP AA”), European Union Data 
Protection Directive 95/46/EC [“EU Directive”]).
In accordance with HIP AA requirements, additional purposes of thi s study  may  include 
publishing of anon ymous patient data from the study .  
10.4 Documentation
10.4.1 Sour ce Documents
Sourc e documents may  include a patient's medical records, hospi[INVESTIGATOR_1332], clinic charts, the 
investigator's patient study files, as well as the resul ts of diagnostic tests such as X -rays, 
laboratory  tests, and electrocardiograms .  The investigator's cop y of th e case report forms 
serves as part of the investigator's record of a patient's stud y
-related data .  
The following information should be entered into the patient's medical record:
Patient’ s name
Patient’ s contact [CONTACT_358228] 192024 -093 Ame ndment 7
87 GDD -TA-T-004 v 2015.10The date that the patient entered the stud y, patient number , and patient medication kit 
number .  
The study  title and/or the protocol number of the study  and the name [CONTACT_358237].
A statement that informed consent was obtained (including the date) .  A statement that 
written authorization (US sites only ), data protection consent (EU sites only ), or other 
country
 and local patient privacy  required documentation for this study  has been 
obtained (including the date).
Dates of all patient visits
All concurrent medications (List all prescripti on and non -prescription medications 
being taken at the time of enrollment .  At each subsequent visit, changes to the list of 
medications should be recorded.)
Occurrence and status of any  adverse events (including an y procedure -related adverse 
events due to complications)
The date the patient exited the study , and a notation as to whether the patient 
completed the study  or reason for discontinuation .
The results of laboratory  tests performed b y the site 
(eg, blood chemistry  and 
hematology , urinal ysis, and pr egnancy  tests)
Key study  variables
Documentation of the patient's medical history
Vital signs, ph ysical examination findings
IOP and ophthalmic examination findings
Dates of SL T or Sham SL T administration procedure
Dates of Bimatoprost SR or Sham administr ation procedure
Documentation of whether any procedure including stud y treatment
administration was performed according to the protoc ol, noting an y deviations (if 
applicable)
 
 

Allergan Confidential Protocol [ADDRESS_446848] follow Section 4.0 of I CH E6, Good Clinical Practice :  
Consolidated Guidance and ALCOA, ie, records must be Attributable, L egible, 
Contemporaneous, Original, and A ccurate.
10.4.2 Case Report Form Completion
The investigator is responsible for ensuring that data are properly  recorded on each pat ient's 
eCRFs and related documents.  An investigator who has signed the protocol signature [CONTACT_160493] (as indicated in the eCRFs) to ensure that the 
observations and findings are recorded on the eCRFs correctl y and completely .  The eCRFs 
are to be submitted to Allergan in a timel y manner at the completion of the study , or as 
otherwise speci fied b y Allergan and will be maintained in a central data repository .
10.4.3 Study Summary
An investigator's summary  will be provided to Allergan within a short time after the 
completion of the study , or as designated b y Allergan .  A summary  is also to be provide d to 
the responsible IRB/IEC.
10.4.[ADDRESS_446849] .  These documents 
should be retained for a longer period, however , if required b y the applicable regulatory 
requirement(s) or if needed by  [CONTACT_78562].
In addition, for countries not falling within the scope of the ICH guidelines, local regulatory  
requirements should be followed regarding the retention of clinical study  documentation.
Allergan requires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutual ly agreed
-upon arrangements can be made for transfer of 
ownership to a suitably  qualified, responsible person.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
89 GDD -TA-T-004 v 2015.1010.5 Labeli ng, Packaging, and Return or Disposal of S tudy 
Medications/T reatments
10.5.1 Labeling/Pack aging
Packaged and labeled study medication will be supp lied by  [CONTACT_78562].
The assembled Bimatoprost SR (or Sham applicator) is individually  packaged into a 
laminated foil po uch with desiccant and sealed .  The entire foil pouch package is terminall y 
sterilized .  Each pouch will be placed into its own carton .  The medication will be identified 
as an investigational product
.  The stud y number and medication kit number will be 
identified on the medication labels.
The study  medication contents are described in Section 5.1andSection 5.2.
10.5.[ADDRESS_446850] supervision of an 
investigator .  
10.5.3 Return or Disposal of S tudy Medications/ Treatments and/ or 
Supplies
All clinical study  medications/treatments and/or supplies will be returned to Allergan or 
Allergan designee for destruction .  Used applicators will be disposed of immediately  in a 
sharps container .
Any malfunctioning applicators should b
e retur ned to Allergan or designee .  Written 
instructions provided by  [CONTACT_358229] a malfunctioning 
applicator to Allergan or its representative.
Allergan Confidential Protocol [ADDRESS_446851] 
on-site visits to review , audit and copy  study -related documents .  These representatives will 
meet with the investigator(s) and appropriate staf f at mutually  convenient times to discuss 
study -related data and ques tions.
10.7 Handling of Biological Specimens
Laboratory  specimens for blood chemistry  panel, hematology  including complete blood 
count with dif ferential, and urinaly sis will be sent to a centralized clinical laboratory  or a 
designated regional facility  with cer tificat ion from a recognized accreditation agency  (eg, 
College of American Pathology  or Clinical Laboratory  Improvement Amendments 
certification) to be assayed using validated methods
.  All blood and urine samples will be 
stored at the centralized clinical labora tory following testing, and will be discarded after a 
time period indicated b y Allergan .  Allergan shall have full ownership rights to any biological 
specimens/samples derived from the study .
See the Covance Laboratory Manual and the Procedu re Manua l for p rocedural details.
10.[ADDRESS_446852] joint cooperation between multiple investigators and sites and 
Allergan personnel .  Authorship will be esta blished prior to the writing of the manuscript .  As 
this study  involves multiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study  except as agreed with Allergan .  
10.9 Coordinat ing Inve stigato r
A signatory  Coordinating I nvestigator will be designated prior to the writing of the Clinical 
Study Report.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
91 GDD -TA-T-004 v 2015.1010.10  
 
 
 
 
 
  
 
 
 
  
 

Allergan Confidential Protocol 192024 -093 Ame ndment 7
92 GDD -TA-T-004 v 2015.1011. References
AGIS Investigators.  The Advanced Glaucoma Intervention Study (AGIS) :  7.  The 
relationship between control o
f intraocular pre ssure and visual field deterioration.  Am J 
Ophthalmol.  2000;130:429-440.
American Academ y of Ophthalmology Glaucoma Panel .  Preferred Practice Pattern®
Guidelines
.  Primary  open -angle glaucoma.  San Francisco, CA :  American Academ y of 
Ophthalmolog y; 2010a.  27 p.
Budenz DL .  A clinician's guide to the assessment and management of nonadherence in 
glaucoma .  Ophthalmology .  2009;1 16:S43 -S47.
Cohen JS, Gross RL , Cheetham JK, VanDenburgh AM, Bernstein P , Whitcup SM .  Two-year 
double -masked comparison o f bimat oprost with timolol in patients with glaucoma or ocular 
hypertension.  Surv Ophthalmol .  2004;49 (Suppl 1):S45- S52.
Cook C, Foster P .  Epi[INVESTIGATOR_358176] :  What’ s new?  Can J Ophthalmol .  
2012;47:[ADDRESS_446853] y:  results from a 1 -year randomised clinical 
trial.  Br J Ophthalmol .  2006;90(12):[ADDRESS_446854] ive laser trabeculoplasty
 v 
argon laser trabeculoplasty :  a prospective randomised clinical trial .  Br J Ophthalmol .  
1999;83(6):718 -
722.
European Glaucoma Society  (EUGS) .  Terminology  and Guidelines for Glaucoma .  4th ed.  
PubliComm :  Italy; 2014 . 187p . 
Francis BA, Ianchulev T , Schofield JK, Minckler DS.  Selective laser trabeculoplasty  as a 
replacement for medical therap y in open -angle glaucoma.  Am J Ophthalmol .  
2005;140(3) :524-525.
Friedman DS .  Introduction
:  new ins ights on enhancing adhere nce to topi[INVESTIGATOR_78533].  Ophthalmology .  2009;1 16:S29.
Allergan Confidential Protocol 192024 -093 Ame ndment 7
93 GDD -TA-T-004 v 2015.10Heijl A, Leske MC, Bengtsson B, Hy man L, Bengtsson B, Hussein M .  Reduction of 
intraocular pressure and glaucoma progression :  results from the earl y manifest glau coma 
trial.  Arch Ophthal mol.  2002;120:1268-1279.
Higginbotham EJ, Schuman JS, Goldber g I, Gross RL , VanDenburgh AM, Chen K, et al
.  
One-year, randomized study  comparing bimatoprost and timolol in glaucoma and ocular 
hypertension.  Arch Ophthalmol .  2002; 120:1286 -1293.
Kass MA, H euer DK , Higginbotham EJ, Johnson CA, Keltner J L, Miller JP , et al .  The 
Ocular Hy pertension T reatment Study :  a randomized trial determines that topi[INVESTIGATOR_358177] s or prevents the onset of primary  open -angle glaucoma .  Arch 
Ophthalmol . 2002;120(6):701 -713; discussion [ADDRESS_446855] y versus medical therap y as initial treatment of glaucoma :  a prospective, 
randomized trial .  J Glau coma .  2012;21(7):460 -468.
Koucheki B, Hashemi H .  Selective laser trabeculoplasty  in the treatment of open -angle 
glaucoma .  J Glaucoma .  2012;21(1):65 - 70.
Kozak KR, Crews BC, Morrow JD, Wang L- H, Ma YH, W einander R, et al .  Metabolism of 
the endocannabino ids, 2 -arachidon ylglycerol and anandamide, into prostaglandin, 
thromboxane, and prostacy
clin gl ycerol esters and ethanolamides .  J Biol Chem .  
2002;277:[ZIP_CODE]-[ZIP_CODE].
Krauss AH, Woodward DF .  Update on the mechanism of action of bima toprost :  a review 
and di scussio
n of new evidence .  Surv Ophthalmol .  2004;49(Suppl 1):S5- S11.
Lichter PR, Musch DC, Gillespie BW , Guire KE, Janz NK, Wren PA, et al .  Interim clinical 
outcomes in the Collaborative Initial Glaucoma T reatment Study comparing initial treatment 
random ized to medications or surgery .  Ophthalmology .  2001;108:1943- 1953.
LUM IGAN®[Package Insert].  Irvine, CA
:  Allergan, Inc .  2012.
Martinez -
de-la-Casa JM, Garcia -Feijoo J, Castillo A, Matilla M, Macias JM, Benitez -del-
Castillo JM, et al .  Selective vs arg on lase r trabeculoplasty :  hypotensive ef ficacy , anterior 
chamber inflammation, and postoperative pain .  Eye (Lond) .  2004;18(5):498-502.
Allergan Confidential Protocol [ADDRESS_446856] i A, Fezza F , et al .  Prostaglandin 
ethanolamides (prostamides)
:  in vi tro pharmacology  and metabolism .  J Pharmacol Exp 
Ther.  2004;309:745-757.
McAlinden C .  Selective laser trabeculoplast y (SLT) vs other treatment modalities for 
glaucoma :  systematic re view .  Eye (Lond) .  2014;28(3):249-258.
Mosaed S, Dustin L , Minc kler DS .  Comparative outcomes between newer and older 
surgeries for glaucoma .  Trans Am Ophthalmol Soc .  2009;107:127- 133; discussion 134 -135.
Nagar M, Luhishi E, Shah N.  Intraocular pressur e control and fluctuation :  the ef fect of 
treatment with selecti ve lase r trabeculoplasty .  Br J Ophthalmol .  2009;93(4):497-501.
Olthof f CM, Schouten JS, van de Borne BW , Webers CA .  Noncompliance with ocular 
hypotensive treatment in patients with glaucoma or ocular h ypertension an evidence -based 
review .  Ophthalmology .  2005 ;112(6):953-961.
Quigley  HA, Broman AT.  The number of people with glaucoma worldwide in 2010 and 
2020.  Br J Ophthalmol .  2006;90(3):262 - 267.
Quigley  HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D .  Risk factors for the 
development of glaucomato us visu
al field loss in ocular h ypertension .  Arch Ophthalmol .  
1994;112:[ADDRESS_446857] y:  a review .  J Glaucoma .  2008;17(6):497-502.
Rolim de Moura CR, P aranhos Jr A, W ormald R .  Laser trabeculoplast y for open angle 
glaucoma .  Cochrane Database S yst Rev .  2007;17(4):CD003919.  47 p.
Stamper RL, Lieberman MF , Drake MV .  Introduction and classification of the glaucomas .  
In:  Becker -Shaf fer’s Diagnosis and Therap y of the Glaucomas .  8th ed.  Amsterdam :  Mosby  
[CONTACT_54469]; 2
009.  p.  1-7.  
Tsai JC .  A comprehensive perspective on patient adherence to topi[INVESTIGATOR_358178] y.  
Ophthalmology .  2009;1 16:S30 -S36.
Varma R, Lee PP , Gol dberg I, Kotak S .  
An assessment of the health and economic burdens 
of glaucoma .  Am J Ophthalmol.  201 1;152:[ADDRESS_446858] y with argon laser trabeculoplasty in the t reatment of open -angle glaucoma.  
Can J Ophthalmol .  2013;48(3):186-192.
Weber A, Ni J, L ing KH, Acheam pong A, Tang-Liu DD, Burk R, et al .  Formation of 
prostamides from anandamide in F AAH knockout mice anal yzed by [CONTACT_358230] .  J L ipid Res .  2004;45:[ADDRESS_446859] for intraocular pressure lowering in glaucoma and ocular 
hypertension:  year 4.  Br J Ophthalmol .  2008;92:[ADDRESS_446860] DF , Chan MF , Burke JA, Cheng -Bennett A, Chen G , Fairbairn CE, et al .  Studies 
on the o cular h ypotensive effects of prostaglandin F2 alpha ester prodrugs and receptor 
selective prostaglandin analogs .  J Ocul Pharmacol .  1994;10:[ADDRESS_446861] (L umigan).  Surv Opht halmol .  2001;45(Suppl 4):S337 -S345 .
Woodward DF , Phelps RL, Krauss AH, W eber A, Short B, Chen J, et al .  Bimatoprost :  A 
novel antiglaucoma agent .  Cardiovasc Drug Rev .  2004;22:103 - 120.
Yu M, I ves D, Ramesha CS .  Synthesis of prostaglandin E2 etha nolamid e from anandamide 
by [CONTACT_358231] -2.  J Biol Chem .  1997;272:21 181-[ZIP_CODE].
Allergan Confidential Protocol 192024 -093 Ame ndment 7
96 GDD -TA-T-004 v 2015.1012. Attachments
Not applicable
12.1 Glossary of Abbr eviations
Term/Abbr eviation Definition
ABMD Anterior Basement Membrane Disease
AC anterior chamber
AGIS Advanced Glaucoma Intervent ion Study
ALT argon laser trabeculoplasty
ANCOV A analysis of covariance
ARMD Age-related macular degeneration
ASC Ambulatory  Surgical Center
BLQ below the limit of quantitation
bpm beats per minute
CFR Code of Federal Regulations
CI confidence interval
DMEK Descemet’ s Membrane Endothelial Keratoplasty
DSEK Descemet’ s Strippi[INVESTIGATOR_358179] y
eCRF electronic case report form
EU European Union
FDA Food and Drug Administration
GCP Good 
Clinical Practice
GLP Good Laboratory  Practic e
H hour
HIPAA Health Insurance Portability  and Accountabili t
yAct
IB Investigator ’s Brochure
ICH International Conference on Harmonisation
IEC independent ethics committee
IOL intraocular lens 
IOP intraocular pressure
IRB institutional review boa rd
ITT intent -to-treat
LOCF last observation carried forward
LT laser trabeculoplast y
Allergan Confidential Protocol 192024 -093 Ame ndment 7
97 GDD -TA-T-004 v 2015.10Term/Abbr eviation Definition
MDF Map-Dot-Fingerprint
MedDRA Medical Dictionary  for Regulatory  Activities
MI Multiple impu tation
MMRM mixed ef fect model for repeated measures
NSAID nonsteroidal anti -inflammatory  drug
OAG open -
angle glaucoma
OHT ocular h ypertension
OU both ey es
PAS peripheral anterior s ynechiae
PLA polyl actic acid
PLGA polylactic -co-glycolic acid
POAG primary  open -angle glaucoma
PP per protocol
RBC red blood cell
SC/T patients with sickle cell disease or trait or other 
hemoglobinopathies
SLT selective l aser trabeculoplasty
SOC system organ class
SOP standard operating procedures
SR sustained release
US [LOCATION_002]
WBC white blood cell
WOCF worst ( postrandomiza tion) observation carried forward
X perform procedure 